<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        4-991-15
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2015
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        REVLIMID 25 mg capsule
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        LENALIDOMIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        25
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Capsule, hard
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        21
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        20682.25
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="CELGENE INTERNATIONAL" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            CELGENE INTERNATIONAL
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 530]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Salehiya Trading Co.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            CELGENE INTERNATIONAL
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L04AX04
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
            <div class="p-20 text-center font-20">
                <div class="p-10 bg-red"><i class="fa fa-times-circle"></i>&nbsp;&#x644;&#x645; &#x64A;&#x62A;&#x645; &#x625;&#x62F;&#x62E;&#x627;&#x644; &#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A;  &#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x644;&#x647;&#x630;&#x627; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621; &#x62D;&#x62A;&#x649; &#x627;&#x644;&#x622;&#x646;</div>
            </div>
    </div>
    <div id="A-div" class="box-data">
            <div class="p-20 text-center font-20">
                <span class="p-10 bg-red"><i class="fa fa-times-circle"></i>&nbsp;&#x644;&#x645; &#x64A;&#x62A;&#x645; &#x625;&#x62F;&#x62E;&#x627;&#x644; &#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A;  &#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x644;&#x647;&#x630;&#x627; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621; &#x62D;&#x62A;&#x649; &#x627;&#x644;&#x622;&#x646;</span>
            </div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                REVLIMID 5 mg, 10 mg, 15 mg and 25 mg hard capsules.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Revlimid 5 mg hard capsules 
Each capsule contains 5 mg of lenalidomide. 
Excipient(s) with known effect 
Each capsule contains 147 mg of lactose (as anhydrous lactose). 
 
Revlimid 10 mg hard capsules 
Each capsule contains 10 mg of lenalidomide. 
Excipient(s) with known effect 
Each capsule contains 294 mg of lactose (as anhydrous lactose). 
 
Revlimid 15 mg hard capsules 
Each capsule contains 15 mg of lenalidomide. 
Excipient(s) with known effect 
Each capsule contains 289 mg of lactose (as anhydrous lactose). 
 
Revlimid 25 mg hard capsules 
Each capsule contains 25 mg of lenalidomide. 
Excipient(s) with known effect 
Each capsule contains 200 mg of lactose (as anhydrous lactose). 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hard capsule. 
 
 
Revlimid 5 mg hard capsules 
White capsules, size 2, marked “REV 5 mg”. 
 
Revlimid 10 mg hard capsules 
Blue-green/pale yellow capsules, size 0, marked “REV 10 mg”. 
 
Revlimid 15 mg hard capsules 
Pale blue/white capsules, size 0, marked “REV 15 mg”. 
 
Revlimid 25 mg hard capsules 
White capsules, size 0, marked “REV 25 mg”. 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Revlimid in combination with bortezomib and dexamethasone is indicated for the treatment of adult patients with untreated multiple myeloma.</p><p>&nbsp;</p><p>Revlimid is indicated for the treatment of adult patients with multiple myeloma as maintenance therapy after autologous stem cell transplantation.</p><p>&nbsp;</p><p>Revlimid in combination with dexamethasone or Revlimid in combination with melphalan and predni sone, each followed by Revlimid maintenance therapy, is indicated for the treatment of adult patients with untreated multiple myeloma who are not eligible for transplant.</p><p>&nbsp;</p><p>Revlimid in combination with dexamethasone is indicated for the treatment of patients with multiple myeloma who have received at least one prior drug therapy.</p><p>&nbsp;</p><p>Revlimid is indicated for the treatment of patients with transfusion-dependent anemia due to low or intermediate 1-risk myelodysplastic syndrome associated with a deletion 5q cytogenetic abnormality with or without other cytogenetic abnormalities.</p><p>&nbsp;</p><p>Revlimid is indicated for the treatment of patients with relapsed or refractory mantle cell lymphoma (MCL) after prior therapy that included bortezomib and chemotherapy/Rituximab.</p><p>&nbsp;</p><p>Revlimid in combination with rituximab (anti-CD20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (Grade 1-3A) (see &ldquo;Properties/Effects&rdquo;)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The treatment must be initiated and monitored by an experienced haematologist or oncologist.</p><p>&nbsp;</p><p>MultipleMyeloma</p><p><em>&nbsp;</em></p><p><em>Revlimid in combination with bortezomib and dexamethasone in patients with untreated multiple myeloma </em></p><p> Initial therapy: Revlimid in combination with bortezomib and dexamethasone</p><p>Treatment with Revlimid in combination with bortezomib and dexamethasone must not be started if the absolute neutrophil count (ANC) is &lt; 1.0 x 10<sup>9</sup>/L and/or the platelet count is &lt; 50 x 10<sup>9</sup>/L.</p><p>&nbsp;</p><p>The recommended initial dose of Revlimid is 25 mg orally once daily, either a) on days 1-14 of each 21-day treatment cycle or</p><p>b) on days 1-21 of each 28-day treatment cycle.</p><p>&nbsp;</p><p>Bortezomib should be administered as a subcutaneous injection (1.3 mg/m<sup>2 </sup>body surface area) twice</p><p>weekly on days 1, 4, 8 and 11 of each 21-day or 28-day cycle.</p><p>&nbsp;</p><p>The recommended dose of dexamethasone is</p><p>a)&nbsp; 20 mg orally once daily on days 1, 2, 4, 5, 8, 9, 11 and 12 or</p><p>b)&nbsp; 40 mg orally once daily on days 1 to 4 and 9 to 12 of each cycle.</p><p>&nbsp;</p><p>Up to eight 21-day or six 28-day cycles (24-week initial therapy) are recommended.</p><p>&nbsp;</p><p>Table 1: Recommended dosing schedule for Revlimid in combination with bortezomib and &nbsp;dexamethasone</p><p><em>&nbsp;</em></p><p><em>&nbsp;</em></p><p><em>&nbsp;</em></p><table border="0" cellspacing="0" cellpadding="0" style="width:636px"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>Up to 8 cycles</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="6" style="vertical-align:top"><p>Day (of the 21-day cycle)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td><p>1</p></td><td><p>2</p></td><td><p>3</p></td><td><p>4</p></td><td><p>5</p></td><td><p>6</p></td><td><p>7</p></td><td><p>8</p></td><td><p>9</p></td><td><p>10</p></td><td><p>11</p></td><td><p>12</p></td><td><p>13</p></td><td><p>14</p></td><td style="vertical-align:top"><p>15-21</p></td></tr><tr><td style="vertical-align:top"><p><em>&nbsp;</em></p><p>Revlimid (25 mg)</p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shapetype
   id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
   path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
   <v:stroke joinstyle="miter"/>
   <v:formulas>
    <v:f eqn="if lineDrawn pixelLineWidth 0"/>
    <v:f eqn="sum @0 1 0"/>
    <v:f eqn="sum 0 0 @1"/>
    <v:f eqn="prod @2 1 2"/>
    <v:f eqn="prod @3 21600 pixelWidth"/>
    <v:f eqn="prod @3 21600 pixelHeight"/>
    <v:f eqn="sum @0 0 1"/>
    <v:f eqn="prod @6 1 2"/>
    <v:f eqn="prod @7 21600 pixelWidth"/>
    <v:f eqn="sum @8 21600 0"/>
    <v:f eqn="prod @7 21600 pixelHeight"/>
    <v:f eqn="sum @10 21600 0"/>
   </v:formulas>
   <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
   <o:lock v:ext="edit" aspectratio="t"/>
  </v:shapetype><v:shape id="Picture_x0020_2245" o:spid="_x0000_i1132" type="#_x0000_t75"
   style='width:5.4pt;height:6.6pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image001.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="7" height="9" src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image002.jpg" /></p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape
   id="Picture_x0020_2247" o:spid="_x0000_i1131" type="#_x0000_t75" style='width:5.4pt;
   height:6.6pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image001.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="7" height="9" src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image002.jpg" /></p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape
   id="Picture_x0020_2249" o:spid="_x0000_i1130" type="#_x0000_t75" style='width:5.4pt;
   height:6.6pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image001.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="7" height="9" src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image002.jpg" /></p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape
   id="Picture_x0020_2251" o:spid="_x0000_i1129" type="#_x0000_t75" style='width:5.4pt;
   height:6.6pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image001.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="7" height="9" src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image002.jpg" /></p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape
   id="Picture_x0020_2253" o:spid="_x0000_i1128" type="#_x0000_t75" style='width:5.4pt;
   height:6.6pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image001.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="7" height="9" src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image002.jpg" /></p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape
   id="Picture_x0020_2255" o:spid="_x0000_i1127" type="#_x0000_t75" style='width:5.4pt;
   height:6.6pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image001.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="7" height="9" src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image002.jpg" /></p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape
   id="Picture_x0020_2257" o:spid="_x0000_i1126" type="#_x0000_t75" style='width:6pt;
   height:6pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image003.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="8" height="8" src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image004.jpg" /></p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape
   id="Picture_x0020_2259" o:spid="_x0000_i1125" type="#_x0000_t75" style='width:6pt;
   height:6pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image003.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="8" height="8" src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image004.jpg" /></p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape
   id="Picture_x0020_2261" o:spid="_x0000_i1124" type="#_x0000_t75" style='width:6pt;
   height:6pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image003.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="8" height="8" src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image004.jpg" /></p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape
   id="Picture_x0020_2263" o:spid="_x0000_i1123" type="#_x0000_t75" style='width:6pt;
   height:6pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image003.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="8" height="8" src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image004.jpg" /></p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape
   id="Picture_x0020_2265" o:spid="_x0000_i1122" type="#_x0000_t75" style='width:6pt;
   height:6pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image003.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="8" height="8" src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image004.jpg" /></p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape
   id="Picture_x0020_2267" o:spid="_x0000_i1121" type="#_x0000_t75" style='width:6pt;
   height:6pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image003.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="8" height="8" src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image004.jpg" /></p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape
   id="Picture_x0020_2269" o:spid="_x0000_i1120" type="#_x0000_t75" style='width:6pt;
   height:6pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image003.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="8" height="8" src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image004.jpg" /></p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape
   id="Picture_x0020_2271" o:spid="_x0000_i1119" type="#_x0000_t75" style='width:6pt;
   height:6pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image003.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="8" height="8" src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image004.jpg" /></p></td><td style="vertical-align:top"><p>_</p></td></tr><tr><td style="vertical-align:top"><p><em>&nbsp;</em></p><p>Bortezomib (1.3 mg/m<sup>2</sup>)</p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape
   id="Picture_x0020_2273" o:spid="_x0000_i1118" type="#_x0000_t75" style='width:5.4pt;
   height:6.6pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image001.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="7" height="9" src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image002.jpg" /></p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape
   id="Picture_x0020_2275" o:spid="_x0000_i1117" type="#_x0000_t75" style='width:3.6pt;
   height:3pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image005.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="5" height="4" src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image006.jpg" /></p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape
   id="Picture_x0020_2277" o:spid="_x0000_i1116" type="#_x0000_t75" style='width:3.6pt;
   height:3pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image005.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="5" height="4" src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image006.jpg" /></p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape
   id="Picture_x0020_2279" o:spid="_x0000_i1115" type="#_x0000_t75" style='width:5.4pt;
   height:6.6pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image001.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="7" height="9" src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image002.jpg" /></p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape
   id="Picture_x0020_2281" o:spid="_x0000_i1114" type="#_x0000_t75" style='width:6pt;
   height:2.4pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image007.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="8" height="3" src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image008.jpg" /></p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape
   id="Picture_x0020_2283" o:spid="_x0000_i1113" type="#_x0000_t75" style='width:6pt;
   height:2.4pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image007.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="8" height="3" src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image008.jpg" /></p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape
   id="Picture_x0020_2285" o:spid="_x0000_i1112" type="#_x0000_t75" style='width:6pt;
   height:2.4pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image007.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="8" height="3" src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image008.jpg" /></p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape
   id="Picture_x0020_2287" o:spid="_x0000_i1111" type="#_x0000_t75" style='width:5.4pt;
   height:6.6pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image001.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="7" height="9" src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image002.jpg" /></p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape
   id="Picture_x0020_2289" o:spid="_x0000_i1110" type="#_x0000_t75" style='width:5.4pt;
   height:2.4pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image009.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="7" height="3" src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image010.jpg" /></p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape
   id="Picture_x0020_2291" o:spid="_x0000_i1109" type="#_x0000_t75" style='width:6pt;
   height:2.4pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image007.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="8" height="3" src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image008.jpg" /></p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape
   id="Picture_x0020_2293" o:spid="_x0000_i1108" type="#_x0000_t75" style='width:5.4pt;
   height:6.6pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image001.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="7" height="9" src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image002.jpg" /></p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape
   id="Picture_x0020_2295" o:spid="_x0000_i1107" type="#_x0000_t75" style='width:6pt;
   height:2.4pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image007.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="8" height="3" src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image008.jpg" /></p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape
   id="Picture_x0020_2297" o:spid="_x0000_i1106" type="#_x0000_t75" style='width:6pt;
   height:2.4pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image007.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="8" height="3" src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image008.jpg" /></p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape
   id="Picture_x0020_2299" o:spid="_x0000_i1105" type="#_x0000_t75" style='width:6pt;
   height:2.4pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image007.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="8" height="3" src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image008.jpg" /></p></td><td style="vertical-align:top"><p>_</p></td></tr><tr><td style="vertical-align:top"><p><em>&nbsp;</em></p><p>Dexamethasone (20 mg)</p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape
   id="Picture_x0020_2301" o:spid="_x0000_i1104" type="#_x0000_t75" style='width:5.4pt;
   height:5.4pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image011.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="7" height="7" src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image012.jpg" /></p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape
   id="Picture_x0020_2303" o:spid="_x0000_i1103" type="#_x0000_t75" style='width:5.4pt;
   height:5.4pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image011.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="7" height="7" src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image012.jpg" /></p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape
   id="Picture_x0020_2305" o:spid="_x0000_i1102" type="#_x0000_t75" style='width:3.6pt;
   height:3pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image005.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="5" height="4" src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image006.jpg" /></p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape
   id="Picture_x0020_2307" o:spid="_x0000_i1101" type="#_x0000_t75" style='width:5.4pt;
   height:5.4pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image011.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="7" height="7" src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image012.jpg" /></p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape
   id="Picture_x0020_2309" o:spid="_x0000_i1100" type="#_x0000_t75" style='width:5.4pt;
   height:6.6pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image001.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="7" height="9" src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image002.jpg" /></p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape
   id="Picture_x0020_2311" o:spid="_x0000_i1099" type="#_x0000_t75" style='width:5.4pt;
   height:5.4pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image013.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="7" height="7" src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image014.jpg" /></p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape
   id="Picture_x0020_2313" o:spid="_x0000_i1098" type="#_x0000_t75" style='width:5.4pt;
   height:5.4pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image013.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="7" height="7" src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image014.jpg" /></p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape
   id="Picture_x0020_2315" o:spid="_x0000_i1097" type="#_x0000_t75" style='width:5.4pt;
   height:6.6pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image001.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="7" height="9" src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image002.jpg" /></p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape
   id="Picture_x0020_2317" o:spid="_x0000_i1096" type="#_x0000_t75" style='width:5.4pt;
   height:5.4pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image011.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="7" height="7" src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image012.jpg" /></p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape
   id="Picture_x0020_2319" o:spid="_x0000_i1095" type="#_x0000_t75" style='width:3.6pt;
   height:3pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image005.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="5" height="4" src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image006.jpg" /></p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape
   id="Picture_x0020_2321" o:spid="_x0000_i1094" type="#_x0000_t75" style='width:5.4pt;
   height:5.4pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image011.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="7" height="7" src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image012.jpg" /></p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape
   id="Picture_x0020_2323" o:spid="_x0000_i1093" type="#_x0000_t75" style='width:5.4pt;
   height:5.4pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image011.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="7" height="7" src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image012.jpg" /></p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape
   id="Picture_x0020_2325" o:spid="_x0000_i1092" type="#_x0000_t75" style='width:5.4pt;
   height:5.4pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image013.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="7" height="7" src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image014.jpg" /></p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape
   id="Picture_x0020_2327" o:spid="_x0000_i1091" type="#_x0000_t75" style='width:5.4pt;
   height:5.4pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image013.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="7" height="7" src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image014.jpg" /></p></td><td style="vertical-align:top"><p>_</p></td></tr></tbody></table><p><em>&nbsp;</em></p><p><em>&nbsp;</em></p><p>or</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:642px"><tbody><tr><td colspan="3" style="vertical-align:top"><p>Up to 6 cycles</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="4" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="15" style="vertical-align:top"><p>Day (of the 28-day cycle)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>1</p></td><td style="vertical-align:top"><p>&nbsp;2</p></td><td style="vertical-align:top"><p>&nbsp;3</p></td><td style="vertical-align:top"><p>&nbsp;4</p></td><td style="vertical-align:top"><p>&nbsp;5</p></td><td style="vertical-align:top"><p>&nbsp;6</p></td><td style="vertical-align:top"><p>&nbsp;7</p></td><td style="vertical-align:top"><p>&nbsp;8</p></td><td style="vertical-align:top"><p>&nbsp;9</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>10</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>11</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>12</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>13</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>14</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>15</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>16</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>17</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>18</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>19</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>20</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>21</p></td><td><p>22-28</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</p><p>Revlimid (25 mg)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape
   id="Picture_x0020_2331" o:spid="_x0000_i1090" type="#_x0000_t75" style='width:5.4pt;
   height:6.6pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image001.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="7" height="9" src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image015.jpg" /></p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape
   id="Picture_x0020_2333" o:spid="_x0000_i1089" type="#_x0000_t75" style='width:5.4pt;
   height:6.6pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image001.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="7" height="9" src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image015.jpg" /></p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape
   id="Picture_x0020_2335" o:spid="_x0000_i1088" type="#_x0000_t75" style='width:5.4pt;
   height:6.6pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image001.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="7" height="9" src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image015.jpg" /></p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape
   id="Picture_x0020_2337" o:spid="_x0000_i1087" type="#_x0000_t75" style='width:5.4pt;
   height:6.6pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image001.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="7" height="9" src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image015.jpg" /></p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape
   id="Picture_x0020_2339" o:spid="_x0000_i1086" type="#_x0000_t75" style='width:5.4pt;
   height:6.6pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image001.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="7" height="9" src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image015.jpg" /></p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape
   id="Picture_x0020_2341" o:spid="_x0000_i1085" type="#_x0000_t75" style='width:5.4pt;
   height:6.6pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image001.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="7" height="9" src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image015.jpg" /></p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape
   id="Picture_x0020_2343" o:spid="_x0000_i1084" type="#_x0000_t75" style='width:5.4pt;
   height:6.6pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image001.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="7" height="9" src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image015.jpg" /></p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape
   id="Picture_x0020_2345" o:spid="_x0000_i1083" type="#_x0000_t75" style='width:5.4pt;
   height:6.6pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image001.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="7" height="9" src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image015.jpg" /></p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape
   id="Picture_x0020_2347" o:spid="_x0000_i1082" type="#_x0000_t75" style='width:5.4pt;
   height:6.6pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image001.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="7" height="9" src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image015.jpg" /></p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape
   id="Picture_x0020_2349" o:spid="_x0000_i1081" type="#_x0000_t75" style='width:5.4pt;
   height:6.6pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image001.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="7" height="9" src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image015.jpg" /></p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape
   id="Picture_x0020_2351" o:spid="_x0000_i1080" type="#_x0000_t75" style='width:5.4pt;
   height:6.6pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image001.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="7" height="9" src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image015.jpg" /></p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape
   id="Picture_x0020_2353" o:spid="_x0000_i1079" type="#_x0000_t75" style='width:5.4pt;
   height:6.6pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image001.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="7" height="9" src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image015.jpg" /></p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape
   id="Picture_x0020_2355" o:spid="_x0000_i1078" type="#_x0000_t75" style='width:5.4pt;
   height:6.6pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image001.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="7" height="9" src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image015.jpg" /></p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape
   id="Picture_x0020_2357" o:spid="_x0000_i1077" type="#_x0000_t75" style='width:5.4pt;
   height:6.6pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image001.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="7" height="9" src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image015.jpg" /></p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape
   id="Picture_x0020_2359" o:spid="_x0000_i1076" type="#_x0000_t75" style='width:5.4pt;
   height:6.6pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image001.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="7" height="9" src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image015.jpg" /></p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape
   id="Picture_x0020_2361" o:spid="_x0000_i1075" type="#_x0000_t75" style='width:5.4pt;
   height:6.6pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image001.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="7" height="9" src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image015.jpg" /></p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape
   id="Picture_x0020_2363" o:spid="_x0000_i1074" type="#_x0000_t75" style='width:5.4pt;
   height:6.6pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image001.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="7" height="9" src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image015.jpg" /></p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape
   id="Picture_x0020_2365" o:spid="_x0000_i1073" type="#_x0000_t75" style='width:5.4pt;
   height:6.6pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image001.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="7" height="9" src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image015.jpg" /></p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape
   id="Picture_x0020_2367" o:spid="_x0000_i1072" type="#_x0000_t75" style='width:5.4pt;
   height:6.6pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image001.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="7" height="9" src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image015.jpg" /></p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape
   id="Picture_x0020_2369" o:spid="_x0000_i1071" type="#_x0000_t75" style='width:5.4pt;
   height:6.6pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image001.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="7" height="9" src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image015.jpg" /></p></td><td style="vertical-align:top"><p>_</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</p><p>Bortezomib (1.3 mg/m<sup>2</sup>)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape
   id="Picture_x0020_2373" o:spid="_x0000_i1070" type="#_x0000_t75" style='width:3.6pt;
   height:3pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image005.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="5" height="4" src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image006.jpg" /></p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape
   id="Picture_x0020_2375" o:spid="_x0000_i1069" type="#_x0000_t75" style='width:3.6pt;
   height:3pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image005.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="5" height="4" src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image006.jpg" /></p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape
   id="Picture_x0020_2377" o:spid="_x0000_i1068" type="#_x0000_t75" style='width:5.4pt;
   height:6.6pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image001.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="7" height="9" src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image015.jpg" /></p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape
   id="Picture_x0020_2379" o:spid="_x0000_i1067" type="#_x0000_t75" style='width:3.6pt;
   height:3pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image005.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="5" height="4" src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image006.jpg" /></p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape
   id="Picture_x0020_2381" o:spid="_x0000_i1066" type="#_x0000_t75" style='width:3.6pt;
   height:3pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image005.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="5" height="4" src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image006.jpg" /></p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape
   id="Picture_x0020_2383" o:spid="_x0000_i1065" type="#_x0000_t75" style='width:3.6pt;
   height:3pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image005.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="5" height="4" src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image006.jpg" /></p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape
   id="Picture_x0020_2385" o:spid="_x0000_i1064" type="#_x0000_t75" style='width:5.4pt;
   height:6.6pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image001.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="7" height="9" src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image015.jpg" /></p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape
   id="Picture_x0020_2387" o:spid="_x0000_i1063" type="#_x0000_t75" style='width:3.6pt;
   height:3pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image005.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="5" height="4" src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image006.jpg" /></p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape
   id="Picture_x0020_2389" o:spid="_x0000_i1062" type="#_x0000_t75" style='width:3.6pt;
   height:3pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image005.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="5" height="4" src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image006.jpg" /></p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape
   id="Picture_x0020_2391" o:spid="_x0000_i1061" type="#_x0000_t75" style='width:5.4pt;
   height:6.6pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image001.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="7" height="9" src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image015.jpg" /></p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape
   id="Picture_x0020_2393" o:spid="_x0000_i1060" type="#_x0000_t75" style='width:3.6pt;
   height:3pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image005.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="5" height="4" src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image006.jpg" /></p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape
   id="Picture_x0020_2395" o:spid="_x0000_i1059" type="#_x0000_t75" style='width:3.6pt;
   height:3pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image005.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="5" height="4" src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image006.jpg" /></p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape
   id="Picture_x0020_2397" o:spid="_x0000_i1058" type="#_x0000_t75" style='width:3.6pt;
   height:3pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image005.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="5" height="4" src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image006.jpg" /></p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape
   id="Picture_x0020_2399" o:spid="_x0000_i1057" type="#_x0000_t75" style='width:3.6pt;
   height:3pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image005.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="5" height="4" src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image006.jpg" /></p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape
   id="Picture_x0020_2401" o:spid="_x0000_i1056" type="#_x0000_t75" style='width:3.6pt;
   height:3pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image005.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="5" height="4" src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image006.jpg" /></p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape
   id="Picture_x0020_2403" o:spid="_x0000_i1055" type="#_x0000_t75" style='width:3.6pt;
   height:3pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image005.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="5" height="4" src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image006.jpg" /></p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape
   id="Picture_x0020_2405" o:spid="_x0000_i1054" type="#_x0000_t75" style='width:3.6pt;
   height:3pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image005.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="5" height="4" src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image006.jpg" /></p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape
   id="Picture_x0020_2407" o:spid="_x0000_i1053" type="#_x0000_t75" style='width:3.6pt;
   height:3pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image005.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="5" height="4" src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image006.jpg" /></p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape
   id="Picture_x0020_2409" o:spid="_x0000_i1052" type="#_x0000_t75" style='width:3.6pt;
   height:3pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image005.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="5" height="4" src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image006.jpg" /></p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape
   id="Picture_x0020_2411" o:spid="_x0000_i1051" type="#_x0000_t75" style='width:3.6pt;
   height:3pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image005.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="5" height="4" src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image006.jpg" /></p></td><td style="vertical-align:top"><p>_</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Dexamethasone</p><p>(40 mg)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape id="Picture_x0020_2415" o:spid="_x0000_i1050"
   type="#_x0000_t75" style='width:5.4pt;height:6.6pt;visibility:visible;
   mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image001.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="7" height="9" src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image015.jpg" /></p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape id="Picture_x0020_2417" o:spid="_x0000_i1049"
   type="#_x0000_t75" style='width:5.4pt;height:6.6pt;visibility:visible;
   mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image001.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="7" height="9" src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image015.jpg" /></p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape id="Picture_x0020_2419" o:spid="_x0000_i1048"
   type="#_x0000_t75" style='width:5.4pt;height:6.6pt;visibility:visible;
   mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image001.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="7" height="9" src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image015.jpg" /></p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape
   id="Picture_x0020_2421" o:spid="_x0000_i1047" type="#_x0000_t75" style='width:3.6pt;
   height:3pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image005.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="5" height="4" src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image006.jpg" /></p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape
   id="Picture_x0020_2423" o:spid="_x0000_i1046" type="#_x0000_t75" style='width:3.6pt;
   height:3pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image005.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="5" height="4" src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image006.jpg" /></p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape
   id="Picture_x0020_2425" o:spid="_x0000_i1045" type="#_x0000_t75" style='width:3.6pt;
   height:3pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image005.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="5" height="4" src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image006.jpg" /></p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape
   id="Picture_x0020_2427" o:spid="_x0000_i1044" type="#_x0000_t75" style='width:3.6pt;
   height:3pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image005.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="5" height="4" src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image006.jpg" /></p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape
   id="Picture_x0020_2429" o:spid="_x0000_i1043" type="#_x0000_t75" style='width:5.4pt;
   height:6.6pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image001.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="7" height="9" src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image015.jpg" /></p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape
   id="Picture_x0020_2431" o:spid="_x0000_i1042" type="#_x0000_t75" style='width:5.4pt;
   height:6.6pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image001.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="7" height="9" src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image015.jpg" /></p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape
   id="Picture_x0020_2433" o:spid="_x0000_i1041" type="#_x0000_t75" style='width:5.4pt;
   height:6.6pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image001.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="7" height="9" src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image015.jpg" /></p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape
   id="Picture_x0020_2435" o:spid="_x0000_i1040" type="#_x0000_t75" style='width:5.4pt;
   height:6.6pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image001.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="7" height="9" src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image015.jpg" /></p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape
   id="Picture_x0020_2437" o:spid="_x0000_i1039" type="#_x0000_t75" style='width:3.6pt;
   height:3pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image005.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="5" height="4" src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image006.jpg" /></p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape
   id="Picture_x0020_2439" o:spid="_x0000_i1038" type="#_x0000_t75" style='width:3.6pt;
   height:3pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image005.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="5" height="4" src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image006.jpg" /></p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape
   id="Picture_x0020_2441" o:spid="_x0000_i1037" type="#_x0000_t75" style='width:3.6pt;
   height:3pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image005.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="5" height="4" src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image006.jpg" /></p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape
   id="Picture_x0020_2443" o:spid="_x0000_i1036" type="#_x0000_t75" style='width:3.6pt;
   height:3pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image005.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="5" height="4" src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image006.jpg" /></p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape
   id="Picture_x0020_2445" o:spid="_x0000_i1035" type="#_x0000_t75" style='width:3.6pt;
   height:3pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image005.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="5" height="4" src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image006.jpg" /></p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape
   id="Picture_x0020_2447" o:spid="_x0000_i1034" type="#_x0000_t75" style='width:3.6pt;
   height:3pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image005.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="5" height="4" src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image006.jpg" /></p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape
   id="Picture_x0020_2449" o:spid="_x0000_i1033" type="#_x0000_t75" style='width:3.6pt;
   height:3pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image005.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="5" height="4" src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image006.jpg" /></p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape
   id="Picture_x0020_2451" o:spid="_x0000_i1032" type="#_x0000_t75" style='width:3.6pt;
   height:3pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image005.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="5" height="4" src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image006.jpg" /></p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape
   id="Picture_x0020_2453" o:spid="_x0000_i1031" type="#_x0000_t75" style='width:3.6pt;
   height:3pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image005.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="5" height="4" src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image006.jpg" /></p></td><td style="vertical-align:top"><p>_</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;&nbsp; Continuation of treatment in patients not receiving stem cell transplantation: Revlimid in combination with dexamethasone until disease progression</p><p>Continued treatment with 25 mg Revlimid orally once daily on days 1-21 of the repeated 28-day cycles in combination with dexamethasone. The recommended dose of dexamethasone is 40 mg orally once daily on days 1, 8, 15 and 22 of the repeated 28-day cycles. Treatment may continue until disease progression or intolerance.</p><p>&nbsp;</p><p>&nbsp;&nbsp; Continuation of treatment: autologous stem cell transplantation</p><p>In patients whose treatment will be continued with autologous stem cell transplantation, mobilisation of haematopoietic stem cells should performed within the first 4 cycles of initial therapy.</p><p>&nbsp;&nbsp;</p><p>Revlimid in patients afterautologous stemcell transplantation</p><p>After autologous stem cell transplantation, maintenance therapy with Revlimid should be initiated after adequate hematologic recovery. Treatment with Revlimid should not be started if the ANC is &lt; 1.0 x 10<sup>9</sup>/L, and/or platelet counts are &lt; 75 x 10<sup>9</sup>/L.</p><p>Recommended dose</p><p>The recommended loading dose is 10 mg Revlimid orally once daily continuously (on days 1-28 of the repeated 28-day cycles) given until disease progression or intolerance. After three 28-day cycles of continuous maintenance therapy with Revlimid, the dose m ay be increased to 15 mg orally once daily if tolerated.</p><p>&nbsp;</p><p>Revlimid incombination with dexamethasone until disease progression in untreated patients who are not eligible fortransplant</p><p>Treatment with Revlimid should not be started if the ANC is &lt; 1.0 x 10<sup>9</sup>/L, and/or platelet counts are &lt; 50 x 10<sup>9</sup>/L.</p><p>&nbsp;</p><p>Recommended dose</p><p>The recommended loading dose is 25 mg Revlimid orally once daily on days 1-21 of the repeated 28- day cycles. The recommended dose of dexamethasone is 40 mg orally once daily on days 1, 8, 15 and 22 of repeated 28-day cycles. Treatment with Revlimid and dexamethasone may be continued until disease progression or intolerance.</p><p>&nbsp;</p><p>&nbsp;</p><p>Revlimid in combination with melphalan and prednisone followed by maintenance monotherapy in un- &nbsp;treated non-transplant patients</p><p>Treatment with Revlimid should not be started if the ANC is &lt; 1.5 x 10<sup>9</sup>/L, and/or platelet counts are &lt; 75 x10<sup>9</sup>/L.</p><p>Recommended dose</p><p>The recommended loading dose is Revlimid 10 mg/day orally on days 1-21 of the repeated 28-day cycles for up to 9 cycles, melphalan 0.18 mg/kg orally on days 1-4 of the repeated 28-day cycles, prednisone 2 mg/kg orally on days 1-4 of repeated 28-day cycles.</p><p>Patients who have completed 9 cycles or who are unable to complete combination therapy due to intolerance will receive Revlimid alone,10 mg/day orally, on days 1-21 of the repeated 28-day cycles until disease progression.</p><p>&nbsp;</p><p>Revlimid in combination with dexamethasone in patients with multiple myeloma who received at least one prior drug therapy</p><p><em>&nbsp;</em></p><p>The recommended starting dose is 25 mg Revlimid orally once daily on days 1&ndash;21 of the repeating 28- day treatment cycles. The dose of dexamethasone recommended during the first 4 treatment cycles is 40 mg orally once daily on days 1&ndash;4, 9&ndash;12 and 17&ndash;20 of each 28-day cycle and subsequently 40 mg once daily on days 1&ndash;4. Treatment should be continued until progression or occurrence of unacceptable toxicities.</p><p>&nbsp;</p><p>&nbsp;</p><p><em><u>Myelodysplastic syndrome</u></em><em> </em></p><p><em>&nbsp;</em></p><p>The recommended starting dose is 10 mg Revlimid orally once daily on days 1-21 of the repeated 28- day treatment cycles. If at least a minor response, i.e. at least a 50% improvement, cannot be demonstrated 16 weeks after the start of the Revlimid therapy , discontinuation of treatment due to lack of efficacy is recommended.</p><p>&nbsp;</p><p>&nbsp;</p><p><em><u>Relapsed or refractory mantle cell lymphoma</u></em><em> </em></p><p>The recommended starting dose of Revlimid is 25 mg orally daily on days 1-21 of repeated 28-day treatment cycles. Treatment should be continued until disease progression or occurrence of unacceptable toxicity.</p><p>&nbsp;</p><p>&nbsp;</p><p><em><u>Follicular lymphoma (FL) in combination with rituximab (R</u></em><em><sup>2</sup></em><em><u> regimen) </u></em></p><p><em>&nbsp;</em></p><p>Treatment with Revlimid must not be started if the absolute neutrophil count (ANC) is &lt;1 x 10<sup>9</sup>/l and/or platelet counts are &lt;50 x 10<sup>9</sup>/l, unless this is the consequence of infiltration of the bone marrow by the lymphoma.</p><p>&nbsp;</p><p>The recommended starting dose of Revlimid is 20 mg orally once daily on days 1-21 of the repeated 28- day treatment cycles for up to 12 treatment cycles. The recommended starting dose of rituximab is 375 mg/m&sup2; intravenously (i.v.) once weekly in cycle 1 (days 1, 8, 15 and 22) and on day 1 of every 28- day cycle for cycles 2 up to and including 5.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Dose adjustment</u></p><p>The dose of Revlimid or other medicinal products used in combination treatment (dexamethasone , melphalan , prednisone, bortezomib, rituximab) should be adjusted based on clinical findings and laboratory values.</p><p>&nbsp;</p><p>The Summary of Product Characteristics for the respective medicinal product should be consulted for toxicity-related dose adjustments for the medicinal products used in a combination treatment other than Revlimid.</p><p>&nbsp;</p><p><u>Haematotoxicity</u></p><p>&nbsp;</p><p><em>Recommended dose adjustments during treatment and resumption of treatment </em></p><p><em>&nbsp;</em></p><p>The following dose adjustments are recommended for the management of Grade 3 or Grade 4 neutropenia or thrombocytopenia, as well as any other Grade 3 or Grade 4 toxicity assessed as lenalidomide-related, as described below according to indication.</p><p>&nbsp;</p><p><em>Revlimid in combination with bortezomib and dexamethasone in patients with untreated multiple myeloma </em></p><p><em>&nbsp;</em></p><p><strong><u>&nbsp;Steps for dose redcution</u> </strong><strong>&nbsp;</strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:397px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Lenalidomide</p></td></tr><tr><td style="vertical-align:top"><p>Initial dose</p></td><td style="vertical-align:top"><p>25 mg</p></td></tr><tr><td style="vertical-align:top"><p>Dose level -1</p></td><td style="vertical-align:top"><p>20 mg</p></td></tr><tr><td style="vertical-align:top"><p>Dose level -2</p></td><td style="vertical-align:top"><p>15 mg</p></td></tr><tr><td style="vertical-align:top"><p>Dose level -3</p></td><td style="vertical-align:top"><p>10 mg</p></td></tr><tr><td style="vertical-align:top"><p>Dose level -4</p></td><td style="vertical-align:top"><p>5 mg</p></td></tr></tbody></table><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dose level -5 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2.5 mg daily or 5 mg</p><p>every 48 h</p><p>&nbsp;&nbsp;</p><p>Thrombocytopenia</p><p><strong>&nbsp;</strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:520px"><tbody><tr><td style="vertical-align:top"><p>Change in platelet count</p></td><td style="vertical-align:top"><p>Recommended course of action</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Drop to &lt; 30 x 10<sup>9</sup>/L</p></td><td style="vertical-align:top"><p>Interrupt lenalidomide treatment and monitor complete blood counts weekly</p></td></tr><tr><td style="vertical-align:bottom"><p>Recovery to &ge; 50 x 10<sup>9</sup>/L</p></td><td style="vertical-align:bottom"><p>Resume lenalidomide at dose level 1</p></td></tr><tr><td style="vertical-align:top"><p>For each subsequent drop below</p><p>&lt; 30 x 10<sup>9</sup>/L</p></td><td style="vertical-align:top"><p>Interrupt lenalidomide treatment</p></td></tr><tr><td style="vertical-align:bottom"><p>Recovery to &ge; 50 x 10<sup>9</sup>/L</p><p><strong>Neutropenia </strong></p></td><td style="vertical-align:top"><p>Continuation of lenalidomide at the next lower dose level. Do not dose below</p><p>2.5 mg once daily.</p></td></tr><tr><td style="vertical-align:top"><p>Change in neutrophil count</p></td><td style="vertical-align:top"><p>Recommended course <sup>a</sup><sub> </sub></p></td></tr><tr><td style="vertical-align:top"><p>First drop to &lt; 0.5 x 10<sup>9</sup>/L or febrile neutropenia (fever &ge; 38&deg;C; &lt; 1 x 10<sup>9</sup>/L)</p></td><td style="vertical-align:top"><p>Interrupt lenalidomide treatment and monitor complete blood counts weekly</p></td></tr><tr><td style="vertical-align:bottom"><p>Recovery to &ge; 1 x 10<sup>9</sup>/L</p></td><td style="vertical-align:bottom"><p>Resume lenalidomide at dose level 1</p></td></tr></tbody></table><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For each subsequent drop below &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Interrupt lenalidomide treatment</p><p>&lt; 0.5 x 10<sup>9</sup>/L or febrile neutropenia</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Return to &ge; 1 x 10<sup>9</sup>/L &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Continuation of lenalidomide at the next</p><p>lower dose level. Do not dose below</p><p>2.5 mg once daily.</p><p>&nbsp;</p><p><!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span><![endif]--><!--[if gte vml 1]><v:group
 id="Group_x0020_123936" o:spid="_x0000_s1041" style='width:192pt;height:.5pt;
 mso-position-horizontal-relative:char;mso-position-vertical-relative:line'
 coordsize="24384,63" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
 <v:shape id="Shape_x0020_141269" o:spid="_x0000_s1042" style='position:absolute;
  width:24384;height:91;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="2438400,9144" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m,l2438400,r,9144l,9144,,e" fillcolor="black" stroked="f"
  strokeweight="0">
  <v:stroke miterlimit="83231f" joinstyle="miter"/>
  <v:path arrowok="t" textboxrect="0,0,2438400,9144"/>
 </v:shape><w:wrap type="none"/>
 <w:anchorlock/>
</v:group><![endif]--><img width="256" height="1" src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image016.gif" /><!--[if mso & !supportInlineShapes & supportFields]><v:shape
 id="_x0000_i1030" type="#_x0000_t75" style='width:192pt;height:.5pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span><![endif]--></p><p><em><sup>a </sup></em><em>If neutropenia is the only toxicity at any dose level, then granulocyte colony stimulating factor (G-CSF) is given at the discretion of the physician, while maintaining the dose level of lenalidomide. </em></p><p><em>&nbsp;</em></p><p><em>&nbsp;</em></p><p><em>Revlimid in patients after autologous stem cell transplantation </em></p><p><em>&nbsp;</em></p><p>Steps for dose reduction</p><table border="0" cellspacing="0" cellpadding="0" style="width:481px"><tbody><tr><td style="vertical-align:bottom"><p><u>&nbsp;</u></p></td><td style="vertical-align:top"><p>Loading dose (10 mg)</p></td><td style="vertical-align:top"><p>If dose increased</p><p><u>(15mg)</u><sup>a</sup><u> </u></p></td></tr><tr><td style="vertical-align:top"><p>Dose level 1</p></td><td style="vertical-align:top"><p>5 mg once daily,</p></td><td style="vertical-align:top"><p>10 mg once daily,</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>continuously</p></td><td style="vertical-align:bottom"><p>continuously</p></td></tr><tr><td style="vertical-align:top"><p>Dose level 2</p></td><td style="vertical-align:top"><p>5 mg once daily on days</p></td><td style="vertical-align:top"><p>5 mg once daily,</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>1-21 of the 28-day cycles</p></td><td style="vertical-align:bottom"><p>continuously</p></td></tr></tbody></table><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dose level 3 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Not applicable &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;5 mg once daily on</p><p>days 1-21 of the 28-day <!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span><![endif]--><!--[if gte vml 1]><v:group
 id="Group_x0020_121802" o:spid="_x0000_s1039" style='width:360.95pt;height:.7pt;
 mso-position-horizontal-relative:char;mso-position-vertical-relative:line'
 coordsize="45840,88" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF
dyTewfKKEqcMCKEmHfgZgaE8wMW+SSwc27JvS/v23KTJgkoXFsu+P+c7Ol5vDoMTe0zZBl/LVVlJ
gV4HY31Xy4/tS3EvRSbwBlzwWMsjZrlprq/W22PELHjb51r2RPFBqax7HCCXIaLnThvSAMTP1KkI
+gs6VLdVdad08ISeCho1ZLN+whZ2jsTzgcsnJwldluLxNDiyagkxOquB2Knae/OLUsyEkjenmdzb
mG/YhlRnCWPnb8C898bRJGtQvEOiVxjYhtLOxs8AySiT4JuDystlVV4WPeM6tK3VaILeDZxIOSsu
ti/jidNGNZ3/J08yC1dNv9v8AAAA//8DAFBLAwQUAAYACAAAACEArTA/8cEAAAAyAQAACwAAAF9y
ZWxzLy5yZWxzhI/NCsIwEITvgu8Q9m7TehCRpr2I4FX0AdZk2wbbJGTj39ubi6AgeJtl2G9m6vYx
jeJGka13CqqiBEFOe2Ndr+B03C3WIDihMzh6RwqexNA281l9oBFTfuLBBhaZ4ljBkFLYSMl6oAm5
8IFcdjofJ0z5jL0MqC/Yk1yW5UrGTwY0X0yxNwri3lQgjs+Qk/+zfddZTVuvrxO59CNCmoj3vCwj
MfaUFOjRhrPHaN4Wv0VV5OYgm1p+LW1eAAAA//8DAFBLAwQUAAYACAAAACEA9NcdRo4CAAAJBwAA
HwAAAGNsaXBib2FyZC9kcmF3aW5ncy9kcmF3aW5nMS54bWzUVclu2zAQvRfoPxC8J5IMJ3GMKAGa
trkUTWAnH8BQlCWUIgmSduR+fYcjUhactOhyqg5cZnmcxxkNr276TpKdsK7VqqTFaU6JUFxXrdqU
9Onx88mCEueZqpjUSpR0Lxy9uX7/7ootN5aZpuUEEJRbspI23ptlljneiI65U22EAl2tbcc8bO0m
qyx7AeROZrM8P8861ip6fYD6yDwjW9v+BZTU/JuobpnaMQeQki+nkhij5P+OzJZqd2fN2jzYEDn/
unuwpK1KCjenWAdXRLOoiGawzY68NgeAvrZdsNd1TXpE2YcRMUTvCQfh/Gwxz8/PKOGgWywuo5o3
92848ebTr9wglOFIWEzCwGWI4yfsilmxyGeJ4p3VW0Oi7H+k68zA9XUai3kxuygS0XXDjCBRlogG
p5TUBOBiPfxxOi+L+Txke8wL1NTW+TuhsSzY7ovzePCmSivWpBXvVVpawT2RWEAeR4vj81hMhvng
F3iHJXmZ1FVTUowjKDu9E48azfxRRUKMB61UU6uxRFP1gm2ySLNBvKnlhHwySvNgDD8VAP6mGf4W
47mwCDzxZkfuIJzerlThGuAQzkxJa8k8tqOu9cIS2XbQEWcXeX4ARrSUa9+vsYx8/0FX+3BjzzBD
O4B+6u9hqKUGeC5bQ0mj7fcjGaZVOr/2eylwg3BCVQ/MshUASRbasFAnT+tYI2ABHA4nbp1YmxXk
HvxRMYTkAmSISKqVqKE/YWsJAmc3z7cSYmShWPBDzkyahkVpPCuaIjDiBP+6lXKELND1LcghnGgc
/ERdQ5SjZz548hjNUKzAFXKRShbojE54slYHfwWvUQpz4Arm4a+GKfay7OgRiDp8tMJLM91f/wAA
AP//AwBQSwMEFAAGAAgAAAAhAJJ9h+AdBwAASSAAABoAAABjbGlwYm9hcmQvdGhlbWUvdGhlbWUx
LnhtbOxZS28bNxC+F+h/WOy9sWS9YiNyYMly3MQvREqKHCmJ2mXMXS5Iyo5uRXLqpUCBtOihAXrr
oSgaoAEa9NIfY8BBm/6IDrkvUqLiB1wgKGwBxu7sN8PhzOzM7PDO3WcR9Y4xF4TFbb96q+J7OB6x
MYmDtv9osP3Zbd8TEsVjRFmM2/4MC//uxqef3EHrI0qSIUN8PAhxhD0QFIt11PZDKZP1lRUxAjIS
t1iCY3g2YTxCEm55sDLm6AQWiOjKaqXSXIkQif0NkCiVoB6Ff7EUijCivK/EYC9GEax+MJmQEdbY
8VFVIcRMdCn3jhFt+yBzzE4G+Jn0PYqEhAdtv6L//JWNOytoPWOicgmvwbet/zK+jGF8tKrX5MGw
WLReb9Sbm4V8DaByEddr9Zq9ZiFPA9BoBDtNdbFltla79QxrgNJLh+yt1latauEN+bUFnTcb6mfh
NSiVX1/Ab293wYoWXoNSfGMB3+isdbZs+RqU4psL+FZlc6vesuRrUEhJfLSArjSatW6+2wIyYXTH
CV9r1Ldbq5nwEgXRUESXWmLCYrks1iL0lPFtACggRZLEnpwleIJGEJNdRMmQE2+XBCEEXoJiJoBc
Wa1sV2rwX/3q+kp7FK1jZHArvUATsUBS+nhixEki2/59kOobkLO3b0+fvzl9/vvpixenz3/N1tai
LL4dFAcm3/ufvvnn1Zfe37/9+P7lt+nS83hh4t/98tW7P/78kHjYcWmKs+9ev3vz+uz7r//6+aVD
+iZHQxM+IBEW3j4+8R6yCDbo0B8P+eU4BiEiJsdmHAgUI7WKQ35PhhZ6f4YocuA62LbjYw6pxgW8
N31qKdwP+VQSh8QHYWQB9xijHcadVnig1jLMPJjGgXtxPjVxDxE6dq3dRbHl5d40gRxLXCK7IbbU
PKQolijAMZaeesaOMHbs7gkhll33yIgzwSbSe0K8DiJOkwzI0IqmkmmHROCXmUtB8Ldlm73HXodR
16638LGNhHcDUYfyA0wtM95DU4kil8gBiqhp8F0kQ5eS/RkfmbiekODpAFPm9cZYCBfPAYf9Gk5/
AGnG7fY9OotsJJfkyCVzFzFmIrfYUTdEUeLC9kkcmtjPxRGEKPIOmXTB95j9hqh78AOKl7r7McGW
u8/PBo8gw5oqlQGinky5w5f3MLPitz+jE4RdqWaTR1aK3eTEGR2daWCF9i7GFJ2gMcbeo88dGnRY
Ytm8VPp+CFllB7sC6z6yY1Xdx1hgTzc3i3lylwgrZPs4YEv02ZvNJZ4ZiiPEl0neB6+bNu9BqYtc
AXBAR0cmcJ9Avwfx4jTKgQAZRnAvlXoYIquAqXvhjtcZt/x3kXcM3sunlhoXeC+BB1+aBxK7yfNB
2wwQtRYoA2aAoMtwpVtgsdxfsqjiqtmmTr6J/dKWboDuyGp6IhKf2wHN9T6N/673gQ7j7IdXjpft
evodt2ArWV2y01mWTHbm+ptluPmupsv4mHz8Tc0WmsaHGOrIYsa66Wluehr/f9/TLHufbzqZZf3G
TSfjQ4dx08lkw5Xr6WTK5gX6GjXwSAc9euwTLZ36TAilfTmjeFfowY+A75nxNhAVn55u4mIKmIRw
qcocLGDhAo40j8eZ/ILIsB+iBKZDVV8JCUQmOhBewgQMjTTZKVvh6TTaY+N02FmtqsFmWlkFkiW9
0ijoMKiSKbrZKgd4hXitbaAHrbkCivcyShiL2UrUHEq0cqIykh7rgtEcSuidXYsWaw4tbivxuasW
tADVCq/AB7cHn+ltv1EHFmCCeRw052Plp9TVuXe1M6/T08uMaUUANNh5BJSeXlO6Lt2e2l0aahfw
tKWEEW62EtoyusETIXwGZ9GpqBdR47K+XitdaqmnTKHXg9Aq1Wjd/pAWV/U18M3nBhqbmYLG3knb
b9YaEDIjlLT9CQyN4TJKIHaE+uZCNIDjlpHk6Qt/lcyScCG3kAhTg+ukk2aDiEjMPUqitq+2X7iB
xjqHaN2qq5AQPlrl1iCtfGzKgdNtJ+PJBI+k6XaDoiyd3kKGT3OF86lmvzpYcbIpuLsfjk+8IZ3y
hwhCrNGqKgOOiYCzg2pqzTGBw7AikZXxN1eYsrRrnkbpGErpiCYhyiqKmcxTuE7lhTr6rrCBcZft
GQxqmCQrhMNAFVjTqFY1LapGqsPSqns+k7KckTTLmmllFVU13VnMWiEvA3O2vFqRN7TKTQw5zazw
aeqeT7lrea6b6xOKKgEGL+znqLoXKAiGauVilmpK48U0rHJ2RrVrR77Bc1S7SJEwsn4zFztnt6JG
OJcD4pUqP/DNRy2QJnlfqS3tOtjeQ4k3DKptHw6XYTj4DK7geNoH2qqirSoaXMGZM5SL9KC47WcX
OQWep5QCU8sptRxTzyn1nNLIKY2c0swpTd/TJ6pwiq8OU30vPzCFGpYdsGa9hX36v/EvAAAA//8D
AFBLAwQUAAYACAAAACEAnGZGQbsAAAAkAQAAKgAAAGNsaXBib2FyZC9kcmF3aW5ncy9fcmVscy9k
cmF3aW5nMS54bWwucmVsc4SPzQrCMBCE74LvEPZu0noQkSa9iNCr1AcIyTYtNj8kUezbG+hFQfCy
MLPsN7NN+7IzeWJMk3ccaloBQae8npzhcOsvuyOQlKXTcvYOOSyYoBXbTXPFWeZylMYpJFIoLnEY
cw4nxpIa0cpEfUBXNoOPVuYio2FBqrs0yPZVdWDxkwHii0k6zSF2ugbSL6Ek/2f7YZgUnr16WHT5
RwTLpRcWoIwGMwdKV2edNS1dgYmGff0m3gAAAP//AwBQSwECLQAUAAYACAAAACEAu+VIlAUBAAAe
AgAAEwAAAAAAAAAAAAAAAAAAAAAAW0NvbnRlbnRfVHlwZXNdLnhtbFBLAQItABQABgAIAAAAIQCt
MD/xwQAAADIBAAALAAAAAAAAAAAAAAAAADYBAABfcmVscy8ucmVsc1BLAQItABQABgAIAAAAIQD0
1x1GjgIAAAkHAAAfAAAAAAAAAAAAAAAAACACAABjbGlwYm9hcmQvZHJhd2luZ3MvZHJhd2luZzEu
eG1sUEsBAi0AFAAGAAgAAAAhAJJ9h+AdBwAASSAAABoAAAAAAAAAAAAAAAAA6wQAAGNsaXBib2Fy
ZC90aGVtZS90aGVtZTEueG1sUEsBAi0AFAAGAAgAAAAhAJxmRkG7AAAAJAEAACoAAAAAAAAAAAAA
AAAAQAwAAGNsaXBib2FyZC9kcmF3aW5ncy9fcmVscy9kcmF3aW5nMS54bWwucmVsc1BLBQYAAAAA
BQAFAGcBAABDDQAAAAA=
">
 <v:shape id="Shape_x0020_141271" o:spid="_x0000_s1040" style='position:absolute;
  width:45840;height:91;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="4584065,9144" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m,l4584065,r,9144l,9144,,e" fillcolor="black" stroked="f"
  strokeweight="0">
  <v:stroke miterlimit="83231f" joinstyle="miter"/>
  <v:path arrowok="t" textboxrect="0,0,4584065,9144"/>
 </v:shape><w:wrap type="none"/>
 <w:anchorlock/>
</v:group><![endif]--><img width="481" height="1" src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image017.gif" /><!--[if mso & !supportInlineShapes & supportFields]><v:shape
 id="_x0000_i1029" type="#_x0000_t75" style='width:360.95pt;height:.7pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span><![endif]-->cycles</p><p>Do not dose below 5 mg once daily on days 1-</p><p>21 of the 28-day cycles</p><p><!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span><![endif]--><!--[if gte vml 1]><v:group
 id="Group_x0020_121801" o:spid="_x0000_s1037" style='width:362.4pt;height:.6pt;
 mso-position-horizontal-relative:char;mso-position-vertical-relative:line'
 coordsize="46024,73" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
 <v:shape id="Shape_x0020_4053" o:spid="_x0000_s1038" style='position:absolute;
  width:46024;height:0;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="4602480,0" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m,l4602480,e" filled="f" strokeweight=".58pt">
  <v:path arrowok="t" textboxrect="0,0,4602480,0"/>
 </v:shape><w:wrap type="none"/>
 <w:anchorlock/>
</v:group><![endif]--><img width="485" height="2" src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image018.gif" /><!--[if mso & !supportInlineShapes & supportFields]><v:shape
 id="_x0000_i1028" type="#_x0000_t75" style='width:362.4pt;height:.6pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span><![endif]--></p><p><em><sup>a </sup></em><em>After three 28-day cycles of continuous maintenance therapy with Revlimid, the dose may be increased to 15 mg orally once daily if tolerated. </em></p><p><em>&nbsp;</em></p><p>Thrombocytopenia</p><table border="0" cellspacing="0" cellpadding="0" style="width:483px"><tbody><tr><td style="vertical-align:top"><p>change in platelet count</p></td><td style="vertical-align:top"><p>Recommended course</p></td></tr><tr><td style="vertical-align:top"><p>Drop to &lt; 30 x 10<sup>9</sup>/L</p></td><td style="vertical-align:top"><p>Interrupt lenalidomide treatment and monitor complete blood counts weekly</p></td></tr><tr><td style="vertical-align:top"><p>Return to &ge; 30 x 10<sup>9</sup>/L</p></td><td><p>Resume lenalidomide at dose level 1</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For each subsequent drop below &lt; &nbsp; Interrupt lenalidomide treatment</p><p>30 x 10<sup>9</sup>/L</p><p>Return to &ge; 30 x 10<sup>9</sup>/L c on t i nua t i on o f lenalidomide at next lower dose <!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span><![endif]--><!--[if gte vml 1]><v:group
 id="Group_x0020_121656" o:spid="_x0000_s1035" style='width:361.45pt;height:.7pt;
 mso-position-horizontal-relative:char;mso-position-vertical-relative:line'
 coordsize="45904,88" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
 <v:shape id="Shape_x0020_141273" o:spid="_x0000_s1036" style='position:absolute;
  width:45904;height:91;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="4590415,9144" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m,l4590415,r,9144l,9144,,e" fillcolor="black" stroked="f"
  strokeweight="0">
  <v:stroke miterlimit="83231f" joinstyle="miter"/>
  <v:path arrowok="t" textboxrect="0,0,4590415,9144"/>
 </v:shape><w:wrap type="none"/>
 <w:anchorlock/>
</v:group><![endif]--><img width="482" height="1" src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image019.gif" /><!--[if mso & !supportInlineShapes & supportFields]><v:shape
 id="_x0000_i1027" type="#_x0000_t75" style='width:361.45pt;height:.7pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span><![endif]-->level</p><p>&nbsp;</p><p>Neutropenia</p><table border="0" cellspacing="0" cellpadding="0" style="width:484px"><tbody><tr><td style="vertical-align:top"><p>Change in neutrophil count</p></td><td style="vertical-align:top"><p>Recommended course<sup>a</sup></p></td></tr><tr><td style="vertical-align:top"><p>First drop to &lt; 0.5 x 10<sup>9</sup>/L</p></td><td style="vertical-align:top"><p>Interrupt lenalidomide treatment and monitor complete blood counts weekly</p></td></tr><tr><td style="vertical-align:bottom"><p><u>&nbsp;Return to &ge; 0.5 x10<sup>9</sup>/L </u></p></td><td style="vertical-align:bottom"><p><u>Resume lenalidomide at dose level 1 </u></p></td></tr><tr><td style="vertical-align:top"><p>For each subsequent drop below &lt;</p><p>0.5 x 10<sup>9</sup>/L</p></td><td style="vertical-align:top"><p>Interrupt lenalidomide treatment</p></td></tr><tr><td><p>Return to &ge; 0.5 x 10<sup>9</sup>/L</p></td><td style="vertical-align:bottom"><p>C ont i n uat i on of lenalidomide at the next lower dose level</p></td></tr></tbody></table><p><em><sup>a&nbsp; </sup></em><em>If neutropenia is the only toxicity at any dose level, then granulocyte colony stimulating factor (G-CSF) is given at the discretion of the physician while maintaining the dose level of lenalidomide. </em></p><p><em>&nbsp;</em></p><p><em>&nbsp;</em><em>&nbsp;</em></p><p><em>Revlimid in combination with dexamethasone in untreated patients who are not eligible for transplant </em></p><p><em>&nbsp;</em></p><p><em>&nbsp;</em></p><p>Steps for dose reduction</p><p><strong>&nbsp;</strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:484px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Lenalidomide</p></td><td style="vertical-align:top"><p>Dexamethasone</p></td></tr><tr><td style="vertical-align:top"><p>Loading dose</p></td><td style="vertical-align:top"><p>25 mg</p></td><td style="vertical-align:top"><p>40 mg</p></td></tr><tr><td style="vertical-align:top"><p>Dose level 1</p></td><td style="vertical-align:top"><p>20 mg</p></td><td style="vertical-align:top"><p>20 mg</p></td></tr><tr><td style="vertical-align:top"><p>Dose level 2</p></td><td style="vertical-align:top"><p>15 mg</p></td><td style="vertical-align:top"><p>12 mg</p></td></tr><tr><td style="vertical-align:top"><p>Dose level 3</p></td><td style="vertical-align:top"><p>10 mg</p></td><td style="vertical-align:top"><p>8 mg</p></td></tr><tr><td style="vertical-align:top"><p>Dose level 4</p></td><td style="vertical-align:top"><p>5 mg</p></td><td style="vertical-align:top"><p>4 mg</p></td></tr><tr><td style="vertical-align:top"><p>Dose level 5</p></td><td style="vertical-align:top"><p>2.5 mg daily or 5 mg every 48 h</p></td><td style="vertical-align:top"><p>Not applicable</p></td></tr><tr><td style="vertical-align:bottom"><p><strong><u>&nbsp;Thrombocytopenia </u></strong>Change in platelet count</p></td><td style="vertical-align:bottom"><p>Recommended course</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Drop to &lt;25 x 10<sup>9</sup>/l</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p><p>Interrupt lenalidomide treatment for the remainder of the cycle<sup>a</sup><sub> </sub></p></td></tr><tr><td style="vertical-align:top"><p>Return to &ge;50 x 10<sup>9</sup>/l</p></td><td colspan="2" style="vertical-align:bottom"><p>Continuation of lenalidomide at a dose 5 mg lower than the previous dose. After a dose of 5 mg, continuation of lenalidomide at a dose of 2.5 mg daily or 5 mg every 48 hours. Do not dose below 2.5 mg daily or 5 mg every 48 hours.</p></td></tr></tbody></table><p>&nbsp;<em>&ordf; If dose-limiting toxicity (DLT) occurs on Day15 of a cycle, the lenalidomide treatment will be inter- </em></p><p><em>rupted for at least the remainder of the respective 28-day cycle. </em></p><p><em>&nbsp;</em></p><p><!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span><![endif]--><!--[if gte vml 1]><v:group
 id="Group_x0020_121654" o:spid="_x0000_s1033" style='width:2.15pt;height:1.1pt;
 mso-position-horizontal-relative:char;mso-position-vertical-relative:line'
 coordsize="27305,13970" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
 <v:shape id="Shape_x0020_141275" o:spid="_x0000_s1034" style='position:absolute;
  width:27305;height:13970;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="27305,13970" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQBkUha5wwAAAN8AAAAPAAAAZHJzL2Rvd25yZXYueG1sRE9ba8Iw
FH4f+B/CEfY2U7vNSzWKiIOBD8XLDzg0x7bYnJQmpvXfL4PBHj+++3o7mEYE6lxtWcF0koAgLqyu
uVRwvXy9LUA4j6yxsUwKnuRguxm9rDHTtucThbMvRQxhl6GCyvs2k9IVFRl0E9sSR+5mO4M+wq6U
usM+hptGpkkykwZrjg0VtrSvqLifH0ZBSaE378ej34Vlnjf9Ib890qDU63jYrUB4Gvy/+M/9reP8
j2k6/4TfPxGA3PwAAAD//wMAUEsBAi0AFAAGAAgAAAAhANvh9svuAAAAhQEAABMAAAAAAAAAAAAA
AAAAAAAAAFtDb250ZW50X1R5cGVzXS54bWxQSwECLQAUAAYACAAAACEAWvQsW78AAAAVAQAACwAA
AAAAAAAAAAAAAAAfAQAAX3JlbHMvLnJlbHNQSwECLQAUAAYACAAAACEAZFIWucMAAADfAAAADwAA
AAAAAAAAAAAAAAAHAgAAZHJzL2Rvd25yZXYueG1sUEsFBgAAAAADAAMAtwAAAPcCAAAAAA==
" path="m,l27305,r,13970l,13970,,e" fillcolor="black" stroked="f"
  strokeweight="0">
  <v:stroke miterlimit="83231f" joinstyle="miter"/>
  <v:path arrowok="t" textboxrect="0,0,27305,13970"/>
 </v:shape><w:wrap type="none"/>
 <w:anchorlock/>
</v:group><![endif]--><img width="3" height="2" src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image020.gif" /><!--[if mso & !supportInlineShapes & supportFields]><v:shape
 id="_x0000_i1026" type="#_x0000_t75" style='width:2.15pt;height:1.1pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span><![endif]--></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Neutropenia &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:483px"><tbody><tr><td style="vertical-align:top"><p>Change &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; neutrophil count</p></td><td style="vertical-align:top"><p>Recommended course<sup>a </sup></p></td></tr><tr><td style="vertical-align:top"><p>First drop to &lt;0.5 x 10<sup>9</sup>/l or &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; febrile &nbsp; neutropenia (fever &ge;38&deg;C; &lt;1 x 10<sup>9</sup>/l) &nbsp;</p><p>Return to &ge;1 x 10<sup>9</sup>/l with neutropenia as the only &nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp; observed toxicity &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</p></td><td style="vertical-align:top"><p>Interrupt lenalidomide treatment</p><p>Resume lenalidomide at loading dose once daily</p></td></tr><tr><td style="vertical-align:top"><p>Return to &ge;0.5 x 10<sup>9</sup>/l when &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dose-dependent</p><p>haematologic &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; toxicities &nbsp;other than neutropenia &nbsp;are observed &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</p></td><td style="vertical-align:top"><p>Resume lenalidomide at dose level 1 once daily</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; For &nbsp;&nbsp; each &nbsp;&nbsp; subsequent</p><p>drop below &lt;0.5 x 10<sup>9</sup>/l Return to &ge;0.5 x 10<sup>9</sup>/l</p></td><td style="vertical-align:top"><p>Interrupt lenalidomide treatment Continuation of lenalidomide at the next lower dose level once daily.</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p><em><sup>a </sup>If neutropenia is the only toxicity at any dose level, then granulocyte colony stimulating factor (G-CSF) is given at the discretion of the physician while maintaining the dose level of lenalidomide. </em></p><p><em>&nbsp;</em></p><p>If lenalidomide dose was reduced due to hematologic DLT, the dose of lenalidomide may be increased again to the next higher dose level (up to the starting dose) at the discretion of the treating physician, provided that continued lenalidomide / dexamethasone therapy resulted in improved bone marrow function (no DLT for at least 2 consecutive cycles and an ANC &ge;1,500/&micro;L with a platelet count &ge; 100,000/&micro;L at the start of a new cycle at the current dose level).</p><p>&nbsp;</p><p><em>Revlimid in combination with melphalan and prednisone followed by maintenance monotherapy in non- transplant patients </em></p><p><em>&nbsp;</em><em>&nbsp;</em></p><p>Steps for dose reduction &nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:479px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Lenalidomide</p></td><td style="vertical-align:top"><p>Melphalan</p></td><td style="vertical-align:top"><p>Prednisone</p></td></tr><tr><td style="vertical-align:top"><p>Loading dose</p></td><td style="vertical-align:top"><p>10 mg<sup>a</sup></p></td><td style="vertical-align:top"><p>0.18 mg/kg</p></td><td style="vertical-align:top"><p>2 mg/kg</p></td></tr><tr><td style="vertical-align:top"><p>Dose level 1</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>7.5 mg daily or 15 mg</p><p>&nbsp;</p><p>every48h</p></td><td style="vertical-align:top"><p>0.14 mg/kg</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>1 mg/kg</p></td></tr><tr><td style="vertical-align:top"><p>Dose level 2</p></td><td style="vertical-align:top"><p>5mg</p></td><td style="vertical-align:top"><p>0.10mg/kg</p></td><td style="vertical-align:top"><p>0.5mg/kg</p></td></tr><tr><td style="vertical-align:top"><p>Dose level 3</p></td><td style="vertical-align:top"><p>2.5 mg daily or 15 mg every 48 h</p></td><td style="vertical-align:top"><p>N/A</p></td><td style="vertical-align:top"><p>0.25 mg/kg</p></td></tr></tbody></table><p><em>&nbsp;</em></p><p><em>&nbsp;</em></p><table border="0" cellspacing="0" cellpadding="0" align="left" style="width:567px"><tbody><tr><td><p>Change in platelet count</p><p>First drop to &lt; 25 x</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 10<sup>9</sup>/l &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</p><p>Return to &ge; 25 x 10<sup>9</sup>/l</p></td><td><p><!--[if gte vml 1]><v:group id="Group_x0020_120100"
   o:spid="_x0000_s1030" style='position:absolute;margin-left:-167.8pt;
   margin-top:-5.3pt;width:362.35pt;height:15.4pt;z-index:-251658240;
   mso-position-horizontal-relative:text;mso-position-vertical-relative:text'
   coordsize="46018,1955" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
   <v:shape id="Shape_x0020_5042" o:spid="_x0000_s1031" style='position:absolute;
    left:120;top:1955;width:45898;height:0;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="4589781,0" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m,l4589781,e" filled="f" strokeweight=".58pt">
    <v:path arrowok="t" textboxrect="0,0,4589781,0"/>
   </v:shape><v:shape id="Shape_x0020_141277" o:spid="_x0000_s1032" style='position:absolute;
    width:45827;height:139;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="4582795,13970" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m,l4582795,r,13970l,13970,,e" fillcolor="black" stroked="f"
    strokeweight="0">
    <v:stroke miterlimit="83231f" joinstyle="miter"/>
    <v:path arrowok="t" textboxrect="0,0,4582795,13970"/>
   </v:shape></v:group><![endif]--><img width="484" height="22" src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image021.gif" />Recommended course</p><p>&nbsp;</p><p>Interrupt lenalidomide treatment</p><p>Resume lenalidomide and melphalan at</p></td></tr><tr><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>Dose level 1</p></td></tr></tbody></table><p><!--[if gte vml 1]><v:group id="Group_x0020_119130"
 o:spid="_x0000_s1028" style='position:absolute;left:0;text-align:left;
 margin-left:62.1pt;margin-top:100.5pt;width:360.85pt;height:.7pt;z-index:251659264;
 mso-position-horizontal-relative:text;mso-position-vertical-relative:text'
 coordsize="45827,88" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
 <v:shape id="Shape_x0020_141279" o:spid="_x0000_s1029" style='position:absolute;
  width:45827;height:91;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="4582795,9144" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQCzXJeMwwAAAN8AAAAPAAAAZHJzL2Rvd25yZXYueG1sRE9ba8Iw
FH4X9h/CGfimiTKnVqPoxsAhFLw8+HhoztrO5qQ0Ueu/N4OBjx/ffb5sbSWu1PjSsYZBX4Egzpwp
OddwPHz1JiB8QDZYOSYNd/KwXLx05pgYd+MdXfchFzGEfYIaihDqREqfFWTR911NHLkf11gMETa5
NA3eYrit5FCpd2mx5NhQYE0fBWXn/cVqwKDS9XZUp6X6Paf0+X0yJ+e07r62qxmIQG14iv/dGxPn
vw2G4yn8/YkA5OIBAAD//wMAUEsBAi0AFAAGAAgAAAAhANvh9svuAAAAhQEAABMAAAAAAAAAAAAA
AAAAAAAAAFtDb250ZW50X1R5cGVzXS54bWxQSwECLQAUAAYACAAAACEAWvQsW78AAAAVAQAACwAA
AAAAAAAAAAAAAAAfAQAAX3JlbHMvLnJlbHNQSwECLQAUAAYACAAAACEAs1yXjMMAAADfAAAADwAA
AAAAAAAAAAAAAAAHAgAAZHJzL2Rvd25yZXYueG1sUEsFBgAAAAADAAMAtwAAAPcCAAAAAA==
" path="m,l4582795,r,9144l,9144,,e" fillcolor="black" stroked="f"
  strokeweight="0">
  <v:stroke miterlimit="83231f" joinstyle="miter"/>
  <v:path arrowok="t" textboxrect="0,0,4582795,9144"/>
 </v:shape><w:wrap type="square"/>
</v:group><![endif]--><img width="481" height="1" src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image017.gif" />Thrombocytopenia</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For each subsequent drop below &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 30 x 10<sup>9</sup>/l</p><table border="0" cellspacing="0" cellpadding="0" style="width:495px"><tbody><tr><td style="vertical-align:top"><p>Return to &ge; 30 x 10<sup>9</sup>/l &nbsp;</p></td><td style="vertical-align:top"><p>Interrupt lenalidomide treatment</p></td></tr></tbody></table><p>Resume lenalidomide at next lower dose level (dose level -2 or -3) once daily.</p><p><strong>Neutropenia </strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:483px"><tbody><tr><td style="vertical-align:top"><p>Change in neutrophil count</p></td><td style="vertical-align:top"><p>Recommended course <sup>a</sup></p></td></tr><tr><td style="vertical-align:top"><p>First fall to &lt; 0,5 x 10<sup>9</sup>/l&ordf;</p><p>&nbsp;</p><p>Return to &ge; 0.5 x 10<sup>9</sup>/L when neu- tropenia is the only observed tox- icity &nbsp;&nbsp; &nbsp;</p></td><td style="vertical-align:top"><p>Interrupt lenalidomide treatment</p><p>Resume lenalidomide at loading dose once daily</p></td></tr><tr><td style="vertical-align:top"><p>Return to &ge; 0.5 x 10<sup>9</sup>/L when dose- dependent haematological toxici- ties other than neutropenia are ob-</p><p>served &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</p></td><td style="vertical-align:top"><p>Resume lenalidomide at Dose level -1 once daily</p></td></tr><tr><td style="vertical-align:top"><p>For each subsequent drop below</p><p>&lt; 0,5 x 10<sup>9</sup>/l &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</p><p>Return to &ge; 0,5 x 10<sup>9</sup>/l</p></td><td style="vertical-align:top"><p>Interrupt lenalidomide treatment</p><p>Continuation of lenalidomide at next lower dose level once daily.</p></td></tr></tbody></table><p>&nbsp;</p><p><sup>a </sup><em>If neutropenia is the only toxicity at any dose level, granulocyte colony stimulating factor (G-CSF) is given at the discretion of the physician while maintaining the dose level of lenalidomide. . </em></p><p><em>&nbsp;</em></p><p>Multiple myeloma with at least one prior therapy, myelodysplastic syndrome and mantle cell lymphoma</p><p><em>&nbsp;</em></p><p>For the indication MM after at least one prior therapy or MDS, treatment with lenalidomide should be interrupted for thrombocytopenia with drop of count to &lt; 25 x 10<sup>9</sup>/L or neutropenia with drop of counts to &lt; 0.5 &times; 10<sup>9</sup>/L.</p><p>&nbsp;</p><p>The indication MCL, treatment with lenalidomide should be interrupted for thrombocytopenia with a drop of counts to &lt; 50 x 10<sup>9</sup>/L or for neutropenia with a drop of count to &lt; 0.5 &times; 10<sup>9</sup>/L or a drop to &lt; 1 x 10<sup>9</sup>/L for at least 7 days or a drop to &lt; 1 x 10<sup>9</sup>/L associated with a temperature of &ge; 38.5&deg;C.</p><p>After platelet/neutrophil counts have normalised, the treatment should be continued at the next lower dose down. The dose should be reduced further in case of recurrence. If toxicity is observed below the lowest dose strength, treatment with lenalidomide should be discontinued.</p><p>&nbsp;</p><p>For MM after at least one prior therapy, the first dose reduction is to 15 mg daily, 10 mg if toxicity recurs, and the 5 mg daily.</p><p>&nbsp;</p><p>For MDS the first dose reduction is 5 mg daily; in case of recurrence, a second dose reduction of 2.5 mg daily or 5 mg every 2 days is recommended. A third dose reduction to 5 mg twice a week is recommended if toxicity recurs.</p><p>&nbsp;</p><p>Switching to another therapy in MCL patients who have failed to respond to a lower dose of Revlimid for more than 3 months.</p><p>&nbsp;</p><p>Follicular lymphoma (FL)</p><p><em>&nbsp;</em></p><p>Steps for dose reduction</p><p><strong>&nbsp;</strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:429px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Lenalidomide</p></td></tr><tr><td style="vertical-align:top"><p>Loading dose<sup>a</sup></p></td><td style="vertical-align:top"><p>20 mg once daily on days 1-21 every</p><p>28 days</p></td></tr><tr><td style="vertical-align:top"><p>Dose level 1</p></td><td style="vertical-align:top"><p>15 mg once daily on days 1-21 every</p><p>28 days</p></td></tr><tr><td style="vertical-align:top"><p>Dose level 2</p></td><td style="vertical-align:top"><p>10 mg once daily on days 1-21 every</p><p>28 days</p></td></tr><tr><td style="vertical-align:top"><p>Dose level 3</p></td><td style="vertical-align:top"><p>5 mg once daily on days 1-21</p><p>every 28 days</p></td></tr><tr><td style="vertical-align:top"><p>Dose level 4 <em><sup>b</sup> </em></p></td><td style="vertical-align:top"><p>2.5 mg once daily on days 1-21 every</p><p>28 days or 5 mg every 48 hours</p></td></tr></tbody></table><p>a&nbsp; <em>For loading dose for patients with renal disorders see section below </em></p><p><em>&nbsp;</em></p><p>b&nbsp; <em>Only for adjusted loading dose for patients with moderate grade renal insufficiency </em></p><p>Thrombocytopenia</p><p><strong>&nbsp;</strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:483px"><tbody><tr><td style="vertical-align:top"><p>Change in platelet count</p></td><td style="vertical-align:top"><p>Recommended course</p></td></tr><tr><td style="vertical-align:top"><p>First drop to &lt;50 x 10<sup>9</sup>/l</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Return to &ge;50 x 10<sup>9</sup>/l</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Interrupt treatment with lenalidomide and monitor complete blood counts weekly</p><p>Resume lenalidomide at dose level 1 on days 1-21 of the 28 day cycle.</p></td></tr><tr><td style="vertical-align:top"><p>For each further drop</p><p>&lt;50 x 10<sup>9</sup>/l &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Return to &ge;50 x 10<sup>9</sup>/l</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Interrupt treatment with lenalidomide and monitor complete blood counts weekly</p><p>Resume lenalidomide at the next lower dose level (dose level 2 or 3 once daily). Do not dose lower than dose level 3. If the loading dose was 10 mg<sup>a</sup>, do not dose lower than dose level 4.</p></td></tr></tbody></table><p>&nbsp;<sup>a </sup><em>see section &ldquo;Patients with renal disorders&rdquo; </em></p><p><em>&nbsp;</em></p><p>Neutropenia</p><p><strong>&nbsp;</strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:565px"><tbody><tr><td style="vertical-align:top"><p>Change in neutrophil count</p></td><td style="vertical-align:top"><p>Recommended course<sup>a</sup></p></td></tr><tr><td style="vertical-align:top"><p>First drop to &lt;1.0 x 10<sup>9</sup>/l for at least 7 days OR drop to &lt;1.0 x 10<sup>9</sup>/l together with fever &ge;38.5&deg;C) OR drop to &lt;0.5 x 10<sup>9</sup>/l</p></td><td style="vertical-align:top"><p>Interrupt treatment with lenalidomide and monitor complete blood counts at least every 7 days</p></td></tr><tr><td style="vertical-align:top"><p>Return to &ge;1.0 x 10<sup>9</sup>/l</p></td><td style="vertical-align:top"><p>Resume lenalidomide at the next lower dose level (dose level 1)</p></td></tr></tbody></table><p>&nbsp;</p><p>With every further drop to under 1.0 x 10<sup>9</sup>/l for at Interrupt treatment with lenalidomide and least 7 days or a drop to &lt;1.0 x 10<sup>9</sup>/l together with monitor complete blood counts at least fever (body temperature &ge;38.5&deg;C) or drop to &lt;0.5 x every 7 days</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 10<sup>9</sup>/l &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <sub>&nbsp;</sub></p><p>Return to &ge;0.5 x 10<sup>9</sup>/l</p><p>Resume lenalidomide at the next lower dose level (dose level 2 or 3). Do not dose lower than dose level 3. If the loading dose was 10 mg<sup>b</sup>, do not dose lower than dose level 4.</p><p>&nbsp;</p><p><!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span><![endif]--><!--[if gte vml 1]><v:group
 id="Group_x0020_118936" o:spid="_x0000_s1026" style='width:424.6pt;height:.5pt;
 mso-position-horizontal-relative:char;mso-position-vertical-relative:line'
 coordsize="53924,63" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
 <v:shape id="Shape_x0020_141281" o:spid="_x0000_s1027" style='position:absolute;
  width:53924;height:91;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="5392420,9144" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m,l5392420,r,9144l,9144,,e" fillcolor="black" stroked="f"
  strokeweight="0">
  <v:stroke miterlimit="83231f" joinstyle="miter"/>
  <v:path arrowok="t" textboxrect="0,0,5392420,9144"/>
 </v:shape><w:wrap type="none"/>
 <w:anchorlock/>
</v:group><![endif]--><img width="566" height="1" src="file:///C:/Users/14118/AppData/Local/Packages/oice_16_974fa576_32c1d314_1719/AC/Temp/msohtmlclip1/01/clip_image022.gif" /><!--[if mso & !supportInlineShapes & supportFields]><v:shape
 id="_x0000_i1025" type="#_x0000_t75" style='width:424.6pt;height:.5pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span><![endif]--></p><p>&nbsp;<em><sup>a </sup></em><em>If neutropenia is the only toxicity at any dose level, then granulocyte colony stimulating factor (G-CSF) is </em></p><p><sub>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sub><em>given at the discretion of the physician </em>while maintaining the dose level of lenalidomide.</p><p><em><sup>b </sup></em><em>see section &ldquo;<u>Patients with renal disorders&rdquo;</u> </em></p><p><em>&nbsp;</em></p><p><em>&nbsp;</em></p><p>&nbsp;Other reasons</p><p>Therapy must be interrupted If a Grade 3 non-scaly rash (with blistering), Grade 3 neuropathy, or Grade 2 allergic reaction occur. Therapy must be resumed after appropriate resolution to &le; Grade 1 at the next lower dose level.</p><p>Revlimid must be discontinued if a scaly rash (with blistering), Grade 4 non-scaly rash (with blistering), Grade 4 neuropathy, or a &ge; Grade 3 allergic reaction occurs.</p><p>If constipation occurs (&ge; Grade 3), the therapy must be interrupted and treatment of the constipation initiated. Therapy may be resumed after resolution of constipation to &le; Grade 2 at the next lower dose level.</p><p>If venous thrombosis/embolism (&ge; Grade 3) occurs, the therapy must be interrupted and anticoagulation initiated. Therapy may be resumed at the physician&rsquo;s discretion ( maintaining dose level).</p><p>Revlimid must be discontinued in the case of angioedema, anaphylaxis,, Grade 4 rash, exfoliative or bullous rash, suspected Stevens- Johnson syndrome (SJS) toxic epidermal necrolysis (TEN), or drug exanthema with eosinophilia and systemic symptoms (DRESS), after discontinuation due to these reactions, treatment should not be resumed.</p><p>&nbsp;</p><p>&nbsp;</p><p>Other Grade 3/4 toxicities</p><p>If other Grade 3/4 toxicities attributed to Revlimid occur, treatment should be discontinued and continued at the physician&rsquo;s discretion at the next lower dose level after resolution of the toxicity to &le; Grade 2.</p><p>&nbsp;</p><p><em>Special dose instructions </em></p><p>Patients with hepatic disorders</p><p>Revlimid has not been studied in patients with hepatic impairment, and there are no specific dose recommendations.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><em><u>Patients with renal disorders</u></em><em> </em></p><p>No dose adjustment is required in mild renal insufficiency (CLcr 80-50 ml/min).</p><p>&nbsp;</p><p>The following dose adjustments are recommended for the treatment of MM patients with a starting dose of 25 mg, for patients with follicular lymphoma with a starting dose of 20 mg and for MM patients or for MDS patients with a starting dose of 10 mg at the beginning and over the course of therapy in the case of moderate (30 &le; CLcr &lt;50 ml/min) or severe renal insufficiency (CLcr &lt;30 ml/min) or end-stage renal insufficiency</p><table border="0" cellspacing="0" cellpadding="0" style="width:571px"><tbody><tr><td rowspan="2" style="vertical-align:top"><p><strong>Renal function (</strong><strong>CLcr</strong><strong>) </strong></p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p><p><strong>Dose adjustment</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Initial dose </strong></p><p><strong>25 mg </strong></p></td><td style="vertical-align:top"><p><strong>Initial dose </strong></p><p><strong>20 mg </strong></p></td><td style="vertical-align:top"><p><strong>Initial dose </strong></p><p><strong>10 mg </strong></p></td></tr><tr><td style="vertical-align:top"><p>Normal renal function/mild renal insufficiency (CLcr &ge;50 ml/min)</p></td><td><p>25 mg daily</p></td><td><p>20 mg daily</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>10 mg daily</p></td></tr><tr><td style="vertical-align:top"><p>Moderate renal insufficiency</p><p>(30 &le; CLcr &lt;50 ml/min)</p></td><td><p>10 mg<sup>a </sup>daily</p></td><td><p>10 mg<sup>c </sup>daily</p></td><td><p>5 mg daily</p></td></tr><tr><td><p>Severe renal insufficiency (CLcr &lt;30 ml/min, no dialysis required)</p></td><td style="vertical-align:bottom"><p>7.5 mg daily or 15 mg<sup>b </sup>every</p><p>48 hours</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>No data available</p></td><td style="vertical-align:bottom"><p>2.5 mg daily&nbsp; or 5 mg every</p><p>48 hours</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>2,5 mg daily</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>End-stage renal insufficiency (CLcr &lt; 30 ml/min, dialysis required)</p></td><td style="vertical-align:top"><p>5 mg daily; On dialysis days,</p><p>the dose must be</p><p>administered after dialysis</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>No data available</p></td><td style="vertical-align:top"><p>or 5 mg three</p><p>times a week;</p><p>On dialysis days, the</p><p>dose must be administered after dialysis</p></td></tr></tbody></table><p><em><sup>a </sup></em><em>After two cycles, the dose can be increased to 15 mg daily if the patient does not respond to the treatment and tolerates the medication. </em></p><p><em><sup>b </sup></em><em>The dose can be increased to 10 mg daily if the patient tolerates the medication. </em></p><p><em><sup>c&nbsp; </sup></em><em>After two cycles the dose can be increased to 15 mg daily, if the patient tolerates the medication. </em></p><p><em>&nbsp;</em></p><p><em>&nbsp;</em></p><p>In the treatment of MCL patients, an effect of renal function on the plasma level of the active substance Revlimid analogous to the observed effect in MM, MDS and FL patients is anticipated. Appropriate dose reduction should be considered in MCL patients with renal impairment. Note that the starting dose of 10 mg should not be exceeded in MCL patients with creatinine clearance between 30 and 60 ml/min.</p><p>&nbsp;</p><p>Elderly patients</p><p><em>&nbsp;</em></p><p>No dose adjustments are required. Since reduced renal function must be expected in elderly patients, renal function should be monitored regularly in this age group. Revlimid has been used in clinical trials in patients up to the age of 95 years.</p><p>&nbsp;</p><p>Patients with untreated multiple myeloma who are not eligible for transplant</p><p><em>&nbsp;</em></p><p>In patients over 75 years of age treated with lenalidomide in combination with dexamethasone, the loading dose of dexamethasone is 20 mg/day on days 1, 8, 15, and 22 of each 28-day treatment cycle.</p><p>&nbsp;</p><p>No dose adjustment is recommended for patients over 75 years of age treated with lenalidomide in combination with melphalan and prednisone.</p><p>&nbsp;</p><p><em>Paediatric patients </em></p><p><em>&nbsp;</em></p><p>Revlimid has not been studied in paediatric patients. Revlimid should therefore not be used in this age group.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>&nbsp;</p><p>Revlimid capsules should be taken at approximately the same time of day with some water, with or without food. The capsules should not be opened or chewed. Hands should be washed immediately after contact with the capsules. Caution should be taken not to inhale the powder contained in the capsules (e.g. if a capsule is damaged) or allow it to come into contact with the skin or mucous membranes. If skin contact occurs, the area should be washed with soap and water, and eyes should be flushed with water in case of contact.</p><p>&nbsp;</p><p>If a dose of Revlimid has been missed and it has been less than 12 hours since the missed dose, the dose can still be taken. If more than 12 hours have passed since the usual time of administration, the dose should no longer be taken. The patient should wait until the next day and then take the next dose at the usual time. 2 doses should not be taken at once.</p><p>&nbsp;</p><p>&nbsp;</p><p>.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Pregnancy 
Women of childbearing potential unless all of the conditions of the i-SECURE (Pregnancy Prevention Programme) are met (see “Warnings and Precautions“). 
Hypersensitivity to lenalidomide or to any of the excipients. 
 
 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pregnancy Prevention Programme </strong></p><p><strong>&nbsp;</strong></p><p>Revlimid is available only through a restricted distribution program, called the Lenalidomide&nbsp; i-SECURE program.</p><p>&nbsp;</p><p><strong>&nbsp;</strong><u>Female</u> <u>Patient Programme</u></p><p>The conditions of the Pregnancy Prevention Programme must be met in all patients unless there is evidence that the patient is unable to become pregnant. <em>Criteria for determining the potential to become pregnant. </em></p><p>A female patient or the female partner of a male patient is considered to have childbearing potential unless she fulfils at least one of the following conditions:</p><p>-&nbsp;&nbsp;&nbsp; Age  50 years and spontaneously amenorrhoeic for  1 year*</p><p>-&nbsp;&nbsp;&nbsp; Confirmed premature ovarian failure</p><p>-&nbsp;&nbsp;&nbsp; Prior bilateral salpingo-oophorectomy, tubal sterilisation or hysterectomy</p><p>-&nbsp;&nbsp;&nbsp; XY genotype, Turner syndrome, uterine aplasia</p><p>* Amenorrhoea after cancer therapy does not rule out childbearing potential. <em>Counselling </em></p><p>Lenalidomide is contraindicated in women of childbearing potential unless all of the following conditions are met:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The patient understands the expected teratogenic risk to the unborn child.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; She understands the need for effective contraception without interruption 4 weeks prior to the start of treatment, during the entire treatment period including treatment interruptions and 4 weeks after the end of treatment.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Even if a female patient of childbearing potential is amenorrhoeic, she must follow all of the recommendations for effective contraception.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; she should be able to adhere to effective contraceptive measures.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; She is informed and understands the consequences of pregnancy and the need to seek medical advice promptly if a pregnancy is suspected.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; She understands the need and is willing to have pregnancy tests performed every 4 weeks.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; She has confirmed that she understands the hazards and necessary safety measures associated with taking lenalidomide.</p><p>&nbsp;</p><p>In the case of women of childbearing potential, the prescribing physician must ensure that</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the patient meets the above conditions.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the patient complies with the conditions for contraception, including confirmation of sufficient understanding.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the patient has used adequate contraceptive measures for at least 4 weeks before the start of treatment and will continue effective contraceptive measures for the entire treatment period including treatment interruptions and for at least 4 weeks after the end of treatment. For patients who require immediate treatment with Lenalidomide, adequate contraception, including the use of condoms, must be implemented for 7 days before the start of treatment.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a negative result of a pregnancy test is obtained before the start of treatment. &nbsp;</p><p><em>Contraception </em></p><p>Women of childbearing potential must use effective contraceptive methods for 4 weeks before starting treatment, for the entire treatment period including treatment interruptions, and for 4 weeks after completing treatment. For patients who require immediate treatment with lenalidomide, effective contraception, including condom use, must be implemented for 7 days before starting treatment. If effective contraceptive methods have not already been used previously, the patient must be referred to a medical counselling centre to receive comprehensive advise regarding effective contraceptive methods.</p><p>The following methods can be considered effective contraceptive methods:</p><p>&nbsp;</p><p><em>Patient-independent methods: </em></p><p><em>&nbsp;</em></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Implant</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medroxyprogesterone acetate depot</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sterilisation</p><p>&nbsp;</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Patient-dependent methods: </em></p><p><em>&nbsp;</em></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abstinence from heterosexual intercourse</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Heterosexual intercourse only with a vasectomised male partner; vasectomy must be confirmed by two negative semen analyses</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Oral contraceptives containing progesterone only.</p><p>&nbsp;</p><p>Due to the increased risk of venous thromboembolism with lenalidomide, combined oral contraceptives are not recommended. If a patient is already using combined oral contraceptives, a switch to another contraceptive method should be considered. The risk of venous thromboembolism persists for 4-6 weeks after completing of treatment with combined oral contraceptives. If other methods cannot be</p><p>used, thrombosis prophylaxis should be considered during the continued use of combined oral contra- ceptives. The patient should be adequately informed about the risk of venous thromboembolism.</p><p>Intrauterine system have an increased risk of infections at the time of insertion and may cause irregular vaginal bleeding. These methods are therefore not recommended.</p><p>&nbsp;</p><p>Pregnancy tests</p><p>Pregnancy tests with a sensitivity of at least 25 mIU/ml hCG must be performed in women of childbear ing potential.</p><p>Any case of a patient with a positive pregnancy test must be reported immediately as per the require- ments of the Pregnancy Prevention Program.</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>- &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Prior to starting treatment </em></p><p>A pregnancy test must be performed during the consultation during which lenalidomide is prescribed or within 3 days prior to the prescribing physician, after the patient has used effective contraception for at least 4 weeks. The test is intended to ensure that the patient is not preg nant when starting treatment with lenalidomide.</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; - &nbsp;&nbsp; <em>Before starting treatment if immediate treatment is necessary </em></p><p>A quantitative serum hCH test should be performed immediately. After effective contraception including use of condom for 7 days, this test must be repeated. If both tests confirm that the patient is not pregnant, treatment may be started.&rdquo;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>- &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; During and at the end of treatment </em></p><p>A pregnancy test must be repeated every 4 weeks including 4 weeks after completion of treatment. These pregnancy tests should be performed during doctor&rsquo;s visit for prescription of lenalidomide or in the three days before the doctor&rsquo;s visit.</p><p>It is best to perform tests, the prescribing and dispensing of lenalidomide on the same day. Lenalidomide must be dispensed within a maximum of 7 days of prescription.</p><p>&nbsp;</p><p>Male Patient Programme</p><p>Clinical data shows that this active substance passes into the sperm of male patients who take Revlimid. Patients with female partners of childbearing potential should therefore use condoms during intercourse during treatment with Revlimid and for 7 days after stopping treatment, . Men taking Revlimid must fulfil the following conditions:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; They must understand the expected teratogenic risk if they are having sexual intercourse with a woman of childbearing potential.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; They must understand and agree to use a condom during the entire treatment period, including treatment interruptions, and for at least 7 days after completion of treatment if they have sexual intercourse with a women of childbearing potential.</p><p>The prescribing physician must ensure that male patients understand the need for and agree to the use of condom, for the entire duration of treatment, including treatment interruptions and for 7 days after completing of treatment if they have sexual intercourse with a women of childbearing potential.</p><p>&nbsp;</p><p>The patients must not donate sperm during treatment with Revlimid and for 7 days afterwards.</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Additional Precautions </em></p><p>Patients must be instructed never to give this medicinal product to anyone else and to return unused capsules to their physician or pharmacist after the end of therapy.</p><p>&nbsp;</p><p>&nbsp;&nbsp;</p><p><strong>Other Warnings and Precautions </strong></p><p>HEMATOLOGIC TOXICITY. Revlimid can cause significant neutropenia and thrombocytopenia.</p><p><em>Neutropenia and thrombocytopenia </em></p><p><em>&nbsp;</em></p><p>The major dose-limiting toxicities of lenalidomide include neutropenia and thrombocytopenia. A complete blood count with differential blood count, platelet count, haemoglobin concentration and haematocrit should therefore be performed.</p><p>&nbsp;</p><p>Interruption of treatment and/or dose reduction may be required (see &ldquo;Dosage/Administration&rdquo;). Patients with neutropenia should be monitored for signs of infection. Patients and physicians are encouraged to look out for signs and symptoms of bleeding, including petechiae and nosebleeds, particularly when medications that may increase the risk of bleeding are used concomitantly. If this type of toxicity is observed, appropriate measures should be taken. For patients with untreated multiple myeloma who are eligible for transplant and who are taking Revlimid in combination with bortezomib and dexamethasone, complete blood count should be assessed every 7 days (once weekly) during the first treatment cycle and then before the start of each subsequent cycle. Monthly monitoring (every 4 weeks) is required if treatment with Revlimid in combination with dexamethasone is continued.</p><p>&nbsp;</p><p>For patients with multiple myeloma after autologous stem cell transplantation taking Revlimid, complete blood counts should be assessed every 7 days (once weekly) for the first two 28-day cycles, every 2 weeks (day 1 and day 15) in the third 28-day cycle and then every 28 days (4 weeks).</p><p>&nbsp;</p><p>For patients with untreated multiple myeloma who are not eligible for transplant and are taking Revlimid in combination with melphalan and prednisone, complete blood count should be assessed every 7 days (1 week) for the first cycle (28-days), every 14 days (2 weeks) until completion of 9 cycles, and every 28 days (4 weeks) thereafter.</p><p>Complete blood count should be monitored every 7 days (weekly) for the first 2 cycles, on day 1 and day 15 of cycle 3, and every 28 days (4 weeks) thereafter in patients with untreated multiple myeloma who are not eligible for transplant and who are taking Revlimid in combination with dexamethasone.</p><p>&nbsp;</p><p>In patients with multiple myeloma who have received at least one prior treatment and who are taking Revlimid in combination with dexamethasone, complete blood count should be checked every 14 days (2 weeks) for the first 12 weeks of therapy and once monthly thereafter.</p><p>&nbsp;</p><p>Patients taking Revlimid for MDS with deletion 5q abnormality, should have their complete blood counts checked once weekly for the first 8 weeks of therapy and once monthly thereafter.</p><p>&nbsp;</p><p>For Patients taking Revlimid for MCL, complete blood counts should be assessed once weekly during the first cycle (28 days), every 2 weeks during cycles 2-4, and then once monthly thereafter.</p><p>&nbsp;</p><p>For patients with pre-treated follicular lymphoma who were treated with Revlimid and rituximab, monitoring should be carried out on a weekly basis in the first three weeks of cycle 1 (28 days), then every 14 days during cycles 2 up to and including 4, and after that, at the beginning of each subsequent cycle.</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Infections with or without neutropenia </em></p><p>Patients with multiple myeloma are prone to developing infections including pneumonia. A higher rate of infections was observed with lenalidomide in combination with dexamethasone than with MPT. Grade &ge; 3 infections occurred in less than one-third of the patients in the context of neutropenia. Patients with known risk factors for the occurrence of infections must be closely monitored. All patients should be instructed to seek</p><p>19</p><p>immediate medical attention at the first sign of infection (e.g., cough, fever, etc.) to allow for early treatment to</p><p>reduce the severity.</p><p>&nbsp;</p><p>In rare cases, reactivation of hepatitis B has been reported in patients who received lenalidomide and had previously been infected with the hepatitis B virus (HBV). In some cases, this resulted in acute liver failure requiring discontinuation of lenalidomide and adequate antiviral treatment. The hepatitis B virus status should be determined before starting treatment with lenalidomide. For patients who test positive for HBV infection, a physician experienced in the treatment of hepatitis B should be consulted. Appropriate caution should be exercised when lenalidomide is used in patients previously infected with HBV. These patients must be closely monitored for signs and symptoms of active HBV infection throughout treatment.</p><p>&nbsp;</p><p>When lenalidomide was used as part of combination therapy in patients over 75 years of age, with ISS Stage III, ECOG PS &ge; 2, or CrCl &lt; 60 mL/min, the rate of intolerance (Grade 3 or 4 adverse events, serious adverse events, treatment discontinuation) was increased. Patients should be carefully evaluated for their ability to tolerate lenalidomide in combination therapy, taking into account their age and other comorbidities.</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Venous and arterial thromboembolic events (VTE/ATE) </em></p><p>In patients with multiple myeloma, the combination with dexamethasone or other chemotherapy (e.g., melphalan and prednisone) is associated with an increased risk of venous thromboembolic events (predominantly deep vein thrombosis and pulmonary embolism). The risk of VTE is lower in multiple myeloma maintenance therapy after autologous stem cell transplantation (ASCT), and in MDS, MCL patients with lenalidomide monotherapy and in FL patients with R<sup>2 </sup>therapy.</p><p>There is an increased risk of arterial thromboembolic events (predominantly myocardial infarction and cerebrovascular events) in patients with multiple myeloma receiving combination therapy with lenalidomide and dexamethasone, and to a lesser extent, with combination of lenalidomide, melphalan and prednisone. The risk of ATE is lower in patients with multiple myeloma receiving lenalidomide as maintenance therapy after autologous stem cell transplantation than in patients with multiple myeloma receiving combination therapy of lenalidomide (either with dexamethasone or melphalan and prednisone).</p><p>&nbsp;</p><p>Patients with known risk factors for the occurrence of thromboembolism &ndash; including previous thrombosis &ndash; must therefore be closely monitored. Patients should thus be advised to seek medical attention for symptoms such as shortness of breath, cough, chest pain or pain and/or swelling of the arms and legs. Measures should be taken to minimise all modifiable risk factors (e.g. smoking cessation, control of hypertension and hyperlipidaemia).</p><p>The concomitant administration of erythropoiesis-stimulating agents or a history of thromboembolic events may also increase thrombosis risk in these patients. Erythropoiesis-stimulating agents, or other substances that may increase the risk of thrombosis, such as hormone replacement therapy, should therefore be used with caution patients with multiple myeloma receiving lenalidomide with dexamethasone. A haemoglobin concentration above 11 g/dL should prompt discontinuation of erythropoiesis-stimulating substances.</p><p>The use of prophylactic anti-thrombotic drugs should be recommended especially in patients with additional thromboembolic risk factors.</p><p>&nbsp;</p><p>The use of anti-thrombotic should be made for each patient individually after careful assessment.</p><p>If a thromboembolic event occurs, treatment with lenalidomide should be discontinued and standard anticoagulation therapy should be initiated . Once the patient&rsquo;s condition has stabilised, lenalidomide treatment may be continued , while maintaining anticoagulation if necessary.</p><p>&nbsp;</p><p><em>Myocardial infarction </em></p><p><em>&nbsp;</em></p><p>There have been reports of myocardial infarction in patients treated with lenalidomide, especially in patients with known risk factors. Patients with known risk factors &ndash; including prior thrombosis &ndash; should be closely monitored and measures should be taken to minimise any modifiable risk factors (such as smoking, hypertension, and hyperlipidaemia).</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Second Primary Malignancies (SPM) </em></p><p>Based on a small number of cases, a numerical difference was observed in clinical studies of previously treated patients with multiple myeloma on lenalidomide/dexamethasone compared with controls, whereby this occurred primarily in cases of basal cell or squamous carcinoma of the skin .</p><p>An increase in secondary primary malignancies, including AML and MDS has been observed in clinical studies of patients with newly diagnosed multiple myeloma, with cases diagnosed in patients receiving lenalidomide in combination with melphalan (frequency of 5.3%) or immediately following high- dose melphalan therapy and ASCT (frequency of 7.5%). The observed frequency of AML and MDS cases in the lenalidomide dexamethasone arm was 0.4%.</p><p>Cases of B-cell malignancies (including Hodgkin&rsquo;s disease) have been observed in clinical studies in which patients received Revlimid after ASCT.</p><p>&nbsp;</p><p>An increase in solid SPMs was observed in patients receiving lenalidomide immediately after high-dose intravenous melphalan (HDM) and ASCT (frequency of 7.7%).</p><p>&nbsp;</p><p>In patients with newly diagnosed multiple myeloma receiving lenalidomide in combination with bortezomib and dexamethasone, the frequency of haematological SPMs was 0.0% to 0.8% and the frequency of solid SPMs was 0.4% to 4.5%.</p><p>&nbsp;</p><p>In the case of FL patients who were being treated with a combination of lenalidomide and rituximab, the frequency of haematologic SPMs was 0.7% and the frequency of solid SPMs was 1.4%.</p><p>&nbsp;</p><p>Before starting treatment witj lenalidomide, both the benefit achieved with lenalidomide and the risk of secondary primary malignancies should be considered. . The physician should carefully examine the patients for the occurrence of secondary primary malignancies prior to and during treatment with the aid of the usual early cancer detection measures and initiate therapy if necessary.</p><p>&nbsp;</p><p><em>Liver Disorders </em></p><p>Liver insufficiency, including fatal cases, has been reported in patients treated with lenalidomide in combination with dexamethasone: acute liver insuffciency, toxic hepatitis, cytolytic hepatitis, cholestatic hepatitis, and mixed cytolytic/cholestatic hepatitis were registered. Mechanisms of severe drug- related hepatotoxicity remain unknown, although in some cases, pre-existing viral liver disease, elevated liver enzyme baseline, and possibly antibiotics treatment may be risk factors.</p><p>Abnormal liver function values, which were generally asymptomatic and reversible treatment interruption, were reported frequently. Once liver function parameters have returned to baseline, treatment at a lower dose may be considered.</p><p>Lenalidomide is mainly excreted via the kidneys. It patients with impaired renal function, impairment dose adjustment is key to preventing plasma levels that could increase the risk of more haematologic side effects or hepatotoxicity. Monitoring of liver function is therefore recommended, especially in case of concomitant or previous viral liver infection or when lenalidomide is administered with medications known to be associated with hepatic impairment .</p><p>&nbsp;</p><p><em>Allergic reactions and sever skin reactions </em></p><p>Cases of angioedema, anaphylaxis and severe dermatological reactions, including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN)and drug exanthema with eosinophilia and systemic symptoms (DRESS) have been reported. DRESS syndrome may manifest as a skin reaction (such as rash or exfoliative dermatitis), associated with eosinophilia, fever, and/or lymphadenopathy with systemic complications such as hepatitis, nephritis, pneumonitis, myocarditis, and/or pericarditis. These e v ent s can be fatal. In the case of Grade 2 or Grade 3 skin rash. Interruption or discontinuation of Revlimid should be considered. Revlimid must be discontinued for angioedema, anaphylaxis, Grade 4 rash, exfoliative or bullous rash suspected SJS, TEN or DRESS after discontinuation of due to these reactions, treatment should not be resumed. Patients with severe grade 4 rash associated with thalidomide treatment should not treated with Revlimid.</p><p><em>Tumor Lysis Syndrome </em></p><p>Tumor lysis syndrome (TLS) may occur, including in lymphoma patients. Patients with a high tumor burden before the start of treatment are at risk. These patients should be monitored closely, especially during the first cycle or during dose-escalation, and appropriate precautionary measures should be taken.</p><p><em>Tumor Flare Reaction </em></p><p>Careful monitoring for signs of tumor flare reaction (TFR) is recommended. A tumor flare can mimic disease progression (PD). In the pivotal study MCL-001, occurred in approximately 10% of patients ; all cases were categorized as Grade 1 or 2 and assessed to be treatment-related. The TFR rate in the NHL-007 study was 13.0%, whereby one event corresponded to a Grade 3 event. In the NHL-008 study, the rate was 4.0% with one serious event amongst the other Grade 1-2 events. Most of the events occurred in cycle 1. In patients with Grade 1 and</p><p>2 TFR, treatment with lenalidomide may be continued at the discretion of the physicians without interruption or modification. In the clinical studies MCL-001, NHL-007 and NHL-008, patients with Grade 1 and 2 TFR were given corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs) and/or narcotic analgesics for the treatment of TFR symptoms. The decision regarding therapeutic measures should be made after careful clinical assessment of the individual patient. In patients with Grade 3 or 4 TFR, treatment with lenalidomide should be withheld until the TFR has resolved to &le; Grade</p><p>1. Patients may be treated for symptoms according to the guidance provided for Grade 1 and 2 TFR.</p><p>&nbsp;</p><p>Early death in MCL patients</p><p>Overall, a discernible increase in early deaths (within 20 weeks) was observed in the MCL-002 study.</p><p>Patients with a high tumour burden at baseline have an increased risk of early death; which was 20% (16/81) in the lenalidomide arm and 7% (2/28) in the control arm. During the 52-week period, the corresponding figures were 40% (32/81) and 21% (6/28).</p><p>&nbsp;</p><p>Rejection reactions after organ transplantation</p><p>Cases of organ transplant rejection during treatment with Revlimid, some of which were fatal, were reported during post-marketing surveillance.. In the majority of cases, the rejection reaction occurred within the first 2 months after the start of treatment with Revlimid. The underlying disease (e.g. amyloidosis), concomitant infections and recent discontinuation or reduction of immunosuppressive therapy were possible factors that contributed to rejection of the organ transplant in the reported cases. The incidence of rejection reactions in organ transplants cannot be reliably estimated due to the limitation of post-marketing safety data. Revlimid was generally permanently discontinued after the occurrence of the rejection reaction. Before starting treatment with Revlimid, the benefit of treatment with Revlimid should be weighed against the risk of possible organ transplant rejection in recipients of organ transplants.</p><p>&nbsp;</p><p>Thyroid function disorder</p><p><em>&nbsp;</em></p><p>Both hypothyroidism and hyperthyroidism have been observed with lenalidomide treatment (see &ldquo;Undesirable Effects&rdquo;). Therefore it is recommended to ensure optimal management of concomitant diseases that may affect thyroid function before starting Revlimid treatment. Monitoring of thyroid function is recommended at the start of treatment and during treatment.</p><p>&nbsp;</p><p>Cardiac electrophysiology</p><p>Prolongation of the QTc interval have been observed in the ECG during treatment with lenalidomide. Concomitant treatment with drugs that prolong the QT interval and treatment in patients with long QT syndrome should only be undertaken with great caution and under regular ECG monitoring.(see</p><p>&rdquo;Properties/Effects).</p><p>&nbsp;</p><p>Immunosuppressive effect</p><p>Lenalidomide l is a strong immunosuppressant. Therefore, caution should be exercised when used concomitantly with other immunomodulating active substances. The effect of vaccination may be compromised . Vaccinations with live organisms should not be performed during treatment with lenalidomide due to the risk of infection.</p><p>Combination therapy</p><p><em>&nbsp;</em></p><p>For information on other medicinal products used in combination with lenalidomide, please refer to the Summary of Product Characteristics of the respective medicinal product.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Lactose intolerance </em></p><p><em>&nbsp;</em></p><p>Revlimid capsules contain lactose. Patients with a rare hereditary galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.</p><p>&nbsp;</p><p>This medicinal product contains less than 1 mmol of sodium (23 mg) per capsule, i.e., it is almost &ldquo;sodium free&rdquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Since lenalidomide is not metabolised via phase I enzymes and is only bound to plasma proteins to a small degree , interactions via cytochrome P450 and protein binding are unlikely.</p><p>Since lenalidomide is actively eliminated via tubular secretion, interactions with other medicinal products that are actively eliminated via tubular secretion are possible. There is little experience with regard to elevated uric acid levels.</p><p>Lenalidomide (10 mg) had no effect on the pharmacokinetics of a concomitantly administered single dose of R-warfarin and S-warfarin. A single 25-mg dose of warfarin had no effect on the pharmacokinetics of concomitantly administered lenalidomide . However, it is not known whether interactions occur in clinical use. Close monitoring of warfarin concentration during treatment is therefore advised.</p><p>Treatment with coumarins is not recommended due to the high risk of thrombocytopenia.</p><p>Dexamethasone (40 mg/day) had no effect on the pharmacokinetics of Revlimid.</p><p>Concomitant administration of lenalidomide 10 mg/day increased the plasma bio-availability of digoxin (0.5 mg, single dose) by 14% with a 90% CI (confidence interval) [0.52%-28.2%]. It is not known whether the effect is different in the given clinical situation (higher lenalidomide doses and concomitant therapy with dexamethasone). Monitoring of digoxin concentration is therefore indicated during treatment with lenalidomide.</p><p>&nbsp;</p><p>Co-administration of multiple doses of the P-gp inhibitor quinidine (600 mg, twice daily) has no clinically relevant effect on the pharmacokinetics of lenalidomide (25 mg).</p><p>Co-administration of lenalidomide (25 mg) and the P-gp inhibitor/substrate temsirolimus (25 mg) does not alter the pharmacokinetics of either drug.</p><p>Erythropoiesis-stimulating agents or other active substances that may increase the risk of thrombosis, such as hormone replacement therapy, should only be used with caution in patients with multiple myeloma receiving lenalidomide with dexamethasone.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Due to the teratogenic potential, lenalidomide must be prescribed under a Pregnancy Prevention Pro- gramme (see section 4.4) unless there is reliable evidence that the patient does not have childbearing potential.</p><p><u>&nbsp;(not in the reference label and information already in section 4.4)</u>&nbsp;</p><p>Pregnancy</p><p>&nbsp;</p><p>There is no clinical data on the use of lenalidomide in pregnant women. Lenalidomide is structurally related to thalidomide. Thalidomide is a substance known to be teratogenic in humans, causing severe, life- threatening birth defects. In an embryo-foetal development study of pregnant female monkeys, lenalidomide caused malformations in the offspring (see also section 5.3 pre-clinical safety data). A teratogenic effect of lenalidomide is expected in humans. . For details about the pregnancy prevention programme, (see section 4.3 Warning and Precautions). For the treatment of male patients, (see section 4.3 Warning and Precautions).</p><p>&nbsp;</p><p>&nbsp;</p><p><u>&nbsp;Lactation </u>&nbsp;</p><p>It is unknown whether lenalidomide passes into breast milk. Therefore, Revlimid should not be used or should be stopped in breastfeeding women.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>A fertility study in rats with lenalidomide doses up to 500 mg/kg (approximately 200 to 500 times the human doses of 25 mg and 10 mg.</p><p>&nbsp;&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies have been conducted on the effects on the ability to drive and operate machinery. Adverse effects such as fatigue, light-headedness, somnolence and blurred vision may occur on Revlimid. Therefore, caution is advised when patients drive or operate machinery.&nbsp;&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Multiple myeloma</p><p><em>&nbsp;</em></p><p><em>Patients with untreated multiple myeloma who are eligible for transplant and received lenalidomide in combination with bortezomib and dexamethasone </em></p><p><em>&nbsp;</em></p><p>In the studies PETHEMA GEM2012 (pooled arms A and B (RVd), n=458) and IFM 2009 (arm A (RVd), n=356), the most common (&ge; 5%) serious adverse reaction reported with lenalidomide in combination with bortezomib and dexamethasone was :</p><p> Pneumonia (5.9%) in PETHEMA GEM2012.</p><p>&nbsp;</p><p>In the PETHEMA GEM2012 study, the most commonly observed adverse reactions with lenalidomide in combination with subcutaneous bortezomib and dexamethasone were peripheral neuropathy (35.2%), neutropenia (31.9%) and thrombocytopenia (25.3%).</p><p>&nbsp;</p><p>In the IFM 2009 study, the most commonly observed adverse reactions with lenalidomide in combination with intravenous bortezomib and dexamethasone were peripheral neuropathy (54.8%) and lymphopenia (52.2%).</p><p><em>Patients with multiple myeloma treated with lenalidomide after autologous stem cell transplantation </em></p><p><em>&nbsp;</em></p><p>In two phase-3, double blind, placebo-controlled, two-arm phase III studies (IFM 2005-02 and CALGB 100104)</p><p>517 patients received lenalidomide and 501 patients received placebo. The side effects from the CALGB 100104 study included not only maintenance period events but also events reported after HDM/ASCT. In IFM 2005-02, study the information on side effects refers only to the maintenance therapy period.</p><p>&nbsp;</p><p>The serious adverse reactions observed more frequently with lenalidomide maintenance therapy (&ge;5%) than with placebo were:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pneumonia (10.6%; collective term)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lung infections (9.4%)</p><p>&nbsp;</p><p>The adverse reactions observed more frequently in both studies with lenalidomide maintenance therapy than with placebo were: neutropenia (79.0%), thrombocytopenia (72.3%), diarrhoea (54.5%), bronchitis</p><p>(47.4%), nasopharyngitis (34.8%), muscle spasms (33.4%), rash (31.7%), leukopenia (31.7%), asthenia (29.7%), cough (27.3%), upper respiratory tract infections (26.8%), fatigue (22.8%), gastroenteritis</p><p>(22.5%), anaemia (21.0%) and fever (20.5%).</p><p>&nbsp;</p><p>&nbsp;</p><p>Patients with untreated multiple myeloma who are not eligible for transplant and received lenalidomide in combination with bortezomib and dexamethasone</p><p><em>&nbsp;</em></p><p>In the SWOG S0777 study (arm B (RVd), n = 262), the serious adverse reactions observed more frequently with lenalidomide in combination with intravenous bortezomib and dexamethasone (&ge;5%) than with lenalidomide in combination with dexamethasone were:</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &bull; &nbsp;&nbsp; Hypotension (6.5%), lung infection (5.7%), dehydration (5.0%).</p><p>&nbsp;</p><p>&nbsp;</p><p>Adverse reactions observed more frequently with lenalidomide in combination with bortezomib and dexamethasone than with lenalidomide in combination with dexamethasone were fatigue (73.7%), peripheral neuropathy (71.8%), thrombocytopenia (57.6%), constipation (56.1%), and hypocalcaemia</p><p>(50.0%).</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Patients with untreated multiple myeloma who received lenalidomide in combination with low dose dexamethasone </em></p><p>In a phase-3, open-label, 3 arm study 535 patients received a combination of lenalidomide and a low dose dexamethasone until disease progression (Rd), 541 patients received the combination of lenalidomide and low-dose dexamethasone until the completion of eighteen 28-day cycles (Rd18), and 547 patients received the combination of melphalan, prednisone and thalidomide (MPT).</p><p>&nbsp;</p><p>Serious side effects observed more frequently (&ge; 5%) with lenalidomide in combination with low-dose dexamethasone (Rd and Rd18) than with melphalan, prednisone and thalidomide (MPT) were:</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pneumonia (9.8%)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Renal failure (also acute; 6.3%)</p><p>&nbsp;</p><p>Side effects that were observed more frequently with Rd or Rd18 than with MPT were:</p><p>diarrhoea (45.5%), fatigue (32.8%), back pain (32.0%), asthenia (28.2%), insomnia (27.6%), rash</p><p>(24.3%), loss of appetite (23.1%), cough (22.7%), fever (21.4%), and muscle cramps (20.5%).</p><p>&nbsp;</p><p><em>Patients with untreated multiple myeloma who received lenalidomide in combination with melphalan and prednisone </em></p><p>A phase-3, double-blind, placebo-controlled, 3-arm study evaluated the safety and efficacy of melphalan, prednisone and lenalidomide (MPR) combination therapy followed by lenalidomide maintenance monotherapy. 152 patients received induction therapy with the orally administered MPR combination followed by lenalidomide as maintenance therapy (MPR+R), 153 patients received induction therapy with orally administered MPR combination followed by maintenance therapy with placebo (MPR+p), and 154 patients received induction therapy with orally administered MPp (MP + placebo) combination followed by maintenance therapy with placebo (MPp+p).</p><p>&nbsp;</p><p>Serious side effects observed more frequently (&ge; 5%) with melphalan, prednisone, and lenalidomide followed by lenalidomide maintenance therapy (MPR+R) or melphalan, prednisone, and lenalidomide followed by placebo (MPR+p) than with melphalan, prednisone and placebo followed by placebo (MPp+p) were:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Febrile neutropenia (6.0%)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Anaemia (5.3%)</p><p>&nbsp;</p><p>Side effects that were observed more frequently with MPR+R or MPR+ p than with MPp+p were: neutropenia (83.3%), anaemia (70.7%), thrombocytopenia (70.0%), leukopenia (38.8%), constipation (34.0%), diarrhoea (33.3%), rash (28.9%), fever (27.0%), peripheral oedema (25.0%), cough (24.0%), loss of appetite (23.7%), and asthenia (22.0%).</p><p>&nbsp;</p><p><em>Patients with multiple myeloma who received at least one prior therapy </em></p><p>In placebo-controlled phase-3 studies, 353 patients received the combination of lenalidomide/dexamethasone, and 350 patients received the combination of placebo/dexamethasone . 325 patients (92%) in the lenalidomide/dexamethasone group, had at least one side effect, as compared with 288 patients (82%) in the placebo/dexamethasone group.</p><p>The most serious adverse reactions observed were venous thromboembolism (deep vein thrombosis, pulmonary embolism) and Grade 4 neutropenia.</p><p>The most frequently observed adverse reaction in the lenalidomide/dexamethasone group were neutropenia (39.4%; Grade 4: 5.1%), thrombocytopenia (18.4%, Grades 3-4: 9.9%), fatigue (27.2%), constipation (23.5%), muscle cramps (20.1%), asthenia (17.6%), anaemia (17.0%), diarrhoea (14.2%) and rash (10.2%), insomnia (26.7%) and muscle weakness (10.1%). Neutropenia and thrombocytopenia occurred primarily in a dose-dependent manner, and were successfully treated by dose reduction.</p><p>&nbsp;</p><p><em><u>Myelodysplasticsyndrome</u></em><em> </em></p><p>In a placebo-controlled phase-3 study, 69 patients received lenalidomide 10 m g once daily and 67 patients received placebo.</p><p>The most serious adverse reactions observed were venous thromboembolisms (deep vein thrombosis, pulmonary embolism), Grades 3-4 neutropenia, febrile neutropenia and Grades 3-4 thrombocytopenia.</p><p>The most frequently observed adverse reactions in the lenalidomide group were neutropenia (76.8%; Grades 3-4: 75.4%), thrombocytopenia (49.3%; Grades 3-4: 40.6%), diarrhoea (37.7%), pruritus (27.5%), nausea (20.3%), fatigue (18.8%), constipation (17.4%), muscle spasm (17.4%), fever (15.9%), nasopharyngitis (14.5%), bronchitis (14.5%) and headache (14.5%). Neutropenia and thrombocytopenia occurred primarily in a dose-dependent manner and were successfully treated by dose reduction.</p><p>&nbsp;</p><p><em><u>Mantle cell lymphoma</u></em><em> </em></p><p>In the pivotal MCL study, a total of 134 patients received at least one dose of Revlimid.</p><p>Infections were the most common type of serious adverse events.</p><p>Pneumonia was most frequently reported serious infection</p><p>The most frequently observed adverse reactions were pneumonia (14.2%; Grade 3-4: 9%), upper respiratory tract infections (12.7%), neutropenia (48.5%; Grade 3-4: 43.3%), thrombocytopenia (35.8%; Grade 3-4: 27.6%), anaemia (30.6%; Grade 3-4: 11.2%), leukopenia (14.9%; Grade 3-4: 6.7%), decreased appetite (14.2%), hypokalaemia (12.7%; Grade 3-4: 2.2%), weight loss (12.7%), cough (28.4%), dyspnoea (17.9%; Grade 3-4: 6%), diarrhoea (31.3%; Grade 3-4: 6%), nausea (29.9%), constipation (15.7%), vomiting (11.9%), rash (22.4%; Grade 3-4: 1.5%), pruritus (17.2%), back pain (13.4%; Grade 3-4: 1.5%), muscle spasms (12.7%), fatigue (33.6%; Grade 3-4: 6.7%), fever 23.1%; Grade 3-4: 2.2%), peripheral oedema (15.7%), and asthenia (14.2%; Grade 3-4: 3%).</p><p>&nbsp;</p><p><em><u>Follicular lymphoma (FL)</u></em><em> </em></p><p><em>&nbsp;</em></p><p>The general safety profile of lenalidomide in combination with rituximab in patients with pre-treated follicular lymphoma is based on data from 146 patients in the NHL-007 study and from 177 patients in the NHL-008 study.</p><p>&nbsp;</p><p>The most serious adverse reactions observed were: febrile neutropenia (2.7%), lung embolism (2.7%) and pneumonia (2.7%).</p><p>&nbsp;</p><p>The most frequently observed adverse reactions in the lenalidomide-rituximab group were neutropenia (58.2%), diarrhoea (30.8 %), leukopenia (28.8 %), constipation (21.9 %), cough (21.9 %) and fatigue (21.9 %).</p><p>&nbsp;</p><p>&nbsp;</p><p>The side effects seen in patients with multiple myeloma, myelodysplastic syndrome, mantle cell lymphoma and follicular lymphoma are listed below by organ system and frequency. Side effects are listed in order of decreasing severity within each frequency category.</p><p>Frequency information: very common (&ge;1/10); common (&ge;1/100, &lt;1/10); uncommon (&ge;1/1000, &lt;1/100); rare (&ge;1/10000, &lt;1/1000); very rare: (&lt;1/10000).</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Infections and infestations</u></p><p>Very common:&nbsp; Bronchitis (47.4%), nasopharyngitis (34.8%), upper respiratory tract infections</p><p>(26.8%), gastroenteritis (22.5%), neutropenic infections (17.9%), pneumonia (17.1%), rhinitis (15.0%), sinusitis (14.0%), influenza (13.3%), urinary tract infec tions (11.6%),</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Common: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;Bacteremia, sepsis, local and systemic infections (bacterial, viral or mycoses),</p><p>cellulitis, oral candidiasis, respiratory tract infection, lung infection, lower respiratory tract infection, infectious enterocolitis .</p><table border="0" cellspacing="0" cellpadding="0" style="width:655px"><tbody><tr><td style="vertical-align:top"><p>Uncommon:</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Atypical pneumonia, <em>pneumocystis carinii </em>pneumonia, subacute endocarditis, oph thalmic herpes, herpes zoster, ear infections, oesophageal candidiasis, viral reacti vation* (hepatitis B virus or herpes zoster).</p></td></tr><tr><td style="vertical-align:top"><p>Very rare:</p></td><td style="vertical-align:top"><p>Progressive multifocal leukoencephalopathy*.</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p><u>Benign, malignant and nonspecifiic neoplasms (including cysts and polyps)</u></p><p>&nbsp;</p><p>Very common: Tumour flare reaction (13.0%)</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:581px"><tbody><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Acute myeloid leukemia, myelodysplastic syndrome, squamous cell carcinoma of the skin, basal cell carcinoma, tumor lysis syndrome.</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Acute T-cell type leukemia</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p><u>Blood and lymphatic system disorders</u></p><p>&nbsp;</p><p>&nbsp;</p><p>Very common: Neutropenia (79.0%), thrombocytopenia (72.3%), anaemia (43.8%), leukopenia (31.7%), lymphopenia (52.2%), febrile neutropenia (17.4%).</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Common: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pancytopenia,</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Uncommon: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Granuolytic anaemia, prolonged coagulation, monocytopenia, leukocytosis,</p><p>lymphadenophathy.</p><p>&nbsp;</p><p><u>Immunesystem disorders</u></p><table border="0" cellspacing="0" cellpadding="0" style="width:644px"><tbody><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Acquired hypogammaglobulinaemia. <em>angioedema<strong>* , </strong></em>acute graft-versus-host reaction*</p></td></tr><tr><td style="vertical-align:bottom"><p>Rare:</p><p>&nbsp;</p></td><td><p>Anaphylaxis*.</p></td></tr><tr><td style="vertical-align:top"><p>Unknown:</p></td><td style="vertical-align:top"><p>Organ transplant rejection*.</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p><u>Endocrine Disorders</u></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Common: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cushing syndrome.</p><p>Uncommon: Adrenal insufficiency, hypothyroidism, hyperthyroidism increased or decreased TSH, hirsutism.</p><p>&nbsp;</p><p><u>Metabolism and nutrition disorders</u></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Very common: &nbsp;&nbsp;&nbsp; Hypocalcaemia (50.0%), decreased appetite (34.4%, hyponatraemia (30.5%),</p><p>hypokalaemia (29.0%), dehydration (16.4%), weight loss (13.5%), hyperglycaemia (11.7%) hypoglycaemia (10.7%).</p><table border="0" cellspacing="0" cellpadding="0" style="width:554px"><tbody><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Anorexia,hypomagnesaemia, fluid retention, weight gain, iron overload, hypophosphataemia, hypercalcaemia, hyperuricaemia.</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Metabolic acidosis, diabetes mellitus, , hypoalbuminaemia, cachexia, gout, ,</p></td></tr></tbody></table><p>hyperphosphataemia, increased appetite.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Psychiatric disorders</u></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Very common: &nbsp;&nbsp;&nbsp;&nbsp; Insomnia (32.8%), depression (10.9%).</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Common: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Delirium, hallucinations, mood swings, anxiety, irritability, sleepiness.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Uncommon: Psychotic disorders, hypomania, delusions, decreased libido, personality changes,</p><p>nervousness, aggression, nightmares.</p><p><u>Nervous system disorders</u></p><table border="0" cellspacing="0" cellpadding="0" style="width:644px"><tbody><tr><td style="vertical-align:top"><p>Very common:</p></td><td style="vertical-align:top"><p>Peripheral neuropathy (71.8%), dysgeusia (30.2%), paresthesia (22.5%), dizziness (29.4%), headache (15.4%).</p></td></tr><tr><td style="vertical-align:top"><p>Common:</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Cerebrovascular disease, syncope, , drowsiness tremor, memory disorders, neuralgia, dysaesthesia, peripheral sensory neuropathy</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p><p>&nbsp;</p><p><u>Eye disorders </u>&nbsp;</p></td><td style="vertical-align:top"><p>Cerebral stroke, leukoencephalopathy, speech disorders, attention disorder, balance disorder, movement disorder, oral paraesthesia, psychomotor hyperactivity, anosmia, ataxia, dyskinesia, motor dysfunction, myasthenic syndrome.</p></td></tr><tr><td style="vertical-align:top"><p>Very common:</p></td><td style="vertical-align:top"><p>Blurred vision (16.0%), cataract (13.7%).</p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Visual disturbances, increased lacrimation, conjunctivitis.</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Blindness, retinal arteriosclerosis, retinal venous thrombosis, keratitis, eye</p></td></tr></tbody></table><p>irritation, dry eyes.</p><p>&nbsp;</p><p><u>Ear and labyrinth disorders</u></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:608px"><tbody><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Vertigo.</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p><p><u>Cardiac disorders</u></p></td><td style="vertical-align:top"><p>Numbness, hearing loss, tinnitus, ear pain.</p></td></tr><tr><td style="vertical-align:bottom"><p>Common:</p></td><td style="vertical-align:bottom"><p>Atrial fibrillation, <em>myocardial infarction </em>heart failure.</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Congestive heart failure, heart valve insufficiency, atrial flutter, ventricular trigeminy,</p></td></tr></tbody></table><p>bradycardia, tachycardia, QT prolongation, pulmonary oedema, arrhythmia.</p><p>&nbsp;</p><p><u>Vascular disorders</u></p><p>&nbsp;</p><p>&nbsp;</p><p>Very common: Hypotension (16.4%), deep vein thrombosis (10.2%). Common:&nbsp; Hypertension, flushing, haematoma</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Uncommon: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Circulatory collapse, ischaemia, phlebitis.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Respiratory ,thoracic and mediastinal disorders</u> &nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Very common: &nbsp;&nbsp;&nbsp;&nbsp; Dyspnoea (30.5%), cough (29.4%).</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Common: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pulmonary embolism, respiratory distress, pleuritic pain, hypoxia, oropharyngeal</p><p>pain, epistaxis, rhinorrhoea, dysphonia, hoarseness, hiccups.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Uncommon: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Asthma, chest pain.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rare: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Interstitial pneumonitis.</p><p>*</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Hepatobiliary disorders</u></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:590px"><tbody><tr><td style="vertical-align:top"><p>Very common:</p></td><td style="vertical-align:top"><p>Abnormal liver function tests such as increased alanine aminotransferase (ALT;</p><p>25.6%), increased aspartate aminotransferase (AST 21.4%) or hyperbilirubinaemia (15.2%); increased alkaline phosphatase in blood (25.2%).</p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>&nbsp;Liver cell damage, hepatotoxicity, increased bilirubin levels in blood</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Hepatic insufficiency.</p></td></tr><tr><td style="vertical-align:top"><p>Not known:</p></td><td style="vertical-align:top"><p>Acute hepatic insufficiency, toxic hepatitis, cytolytic hepatitis, cholestatic hepatitis,</p></td></tr></tbody></table><p>mixed cytolytic/cholestatic hepatitis</p><p><u>Gastrointestinal disorders</u></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:647px"><tbody><tr><td style="vertical-align:top"><p>Very common:</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Constipation (56.1%), diarrhoea (54.5%), nausea (37.4%), dyspepsia (19.1%), vomiting (17.6%), abdominal pain (14.7%), stomatitis (12.2%), dry mouth (11.5%).</p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Small intestinal obstruction, gastritis, abdominal distension, upper abdominal pain, , bloating.</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Gastrointestinal bleeding, colitis, proctitis, dysphagia, haemorrhoids, mouth pain, bleeding gums.</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Pancreatitis</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Skin and subcutaneous tissue disorders</u></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:587px"><tbody><tr><td style="vertical-align:top"><p>Very common:</p></td><td style="vertical-align:top"><p>Rash (31.7%), pruritus (27.5%), dry skin (10.6%).</p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Facial oedema, erythema, folliculitis, hyperpigmentation, exanthema, increased sweating, hair loss, night sweats.</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Erythema nodosum, urticaria, eczema, hyperkeratosis, skin fissures, acne, lichen sclerosus, photosensitivity reaction, burning skin, flaking skin.</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Stevens-Johnson syndrome, toxic epidermal necrolysis</p></td></tr><tr><td style="vertical-align:bottom"><p>Very rare:</p></td><td style="vertical-align:bottom"><p>Drug exanthema with eosinophilia and systemic symptoms*.</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p><u>Musculoskeletal and connective tissue disorders</u></p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Very common: Muscle spasms (33.4%), back pain (33.2%), muscle weakness (24.4%), muscle</p><p>cramps (20.1%), arthralgia (19.0%), limb pain (17.9%), myalgia (14.9%), skeletal muscle pain (14.8%), bone pain (11.8%), musculoskeletal chest pain (11.3%), Common: Myopathy, peripheral swelling, neck pain.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Uncommon: Osteonecrosis, muscle atrophy, spondylitis, joint swelling, skeletal muscle</p><p>stiffness, local swelling.</p><p>&nbsp;</p><p><u>Renal and urinary disorders</u></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Common: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Renal insufficiency, renal failure (also acute), acute renal damage</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Uncommon: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Frequent urination, renal tubular necrosis, urinary retention, acquired Fanconi</p><p>syndrome, urinary incontinence.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Reproductive system and breast disorders</u></p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Common: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Erectile dysfunction, gynaecomastia, metrorrhagia, painful nipples.</p><p><u>General disorders and administration site conditions</u></p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Very common: Fatigue (73.7%), peripheral oedema (46.6%), asthaenia (29.7%), fever (23.1%),</p><p>Common: Fall, chills, noncardiac chest pain, bruising, malaise Uncommon: Thirst, feeling cold</p><p>&nbsp;</p><p>* = Post-marketing experience</p><p>&nbsp;</p><p>Reporting suspected side effects after market authorisation is extremely important. This facilitates the continuous monitoring of the risk-benefit relationship of the medicinal product. Healthcare professionals are requested to report any suspicion of a new or serious side effect.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>To report any side effect(s): </strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong><em>Saudi Arabia: </em></strong></p><p><strong><em>&nbsp;</em></strong></p><p>The National Pharmacovigilance Centre (NPC)</p><p>Fax: +966-11-205-7662</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website<u>: https://ade.sfda.gov.sa</u></p><p><strong>&nbsp;</strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:597px"><tbody><tr><td style="vertical-align:top"><p><strong><em>United Arab Emirates: </em></strong></p><p><strong><em>&nbsp;</em></strong></p><p>Pharmacovigilance and Medical Device Section</p><p>P.O. Box: 1853 Dubai UAE Tel: 80011111</p><p>Email: pv@mohap.gov.ae</p><p>Drug Department and Prevention</p><p>Ministry of Health &amp; Prevention</p><p>Dubai</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong><em>Oman: </em></strong></p><p><strong><em>&nbsp;</em></strong></p><p>Department of Pharmacovigilance &amp; Drug Information</p><p>Directorate General of Pharmaceutical Affairs &amp; Drug Control</p><p>Ministry of Health, Sultanate of Oman</p><p>Phone Nos. 00968 22357686/00968 22357687</p><p>Fax: 00968 22358489</p><p>Email: pharma-vigil@moh.gov.om</p><p>Website: www.moh.gov.om</p><table border="0" cellspacing="0" cellpadding="0" align="left" style="width:609px"><tbody><tr><td style="vertical-align:bottom"><p><strong><em>Iraq: </em></strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Iraqi Pharmacovigilance center, Ministry of Health, Iraq</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mobile: 00964 7807820490</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Email: <u>iraqiphvc@moh.gov.iq</u></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: <u>www.tec-moh.com</u></p><p>&nbsp;</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><strong><em>&nbsp;</em></strong></p><p>&nbsp;</p><p><strong><em>Other Countries: </em></strong></p><p><strong>-</strong> Please contact the relevant competent authority.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The main dose-limiting toxicity in studies was of haematological nature. In the case of an overdose, monitoring (symptoms, laboratory) and supportive measures are indicated.</p><p>Lenalidomide is poorly dialysable.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>ATC Code: L04AX04.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Mechanism of action /</u></p><p>Lenalidomide is a derivative of thalidomide and is present as a racemic mixture. It has both immunomodulatory and anti-angiogenic properties.</p><p>Lenalidomide binds to the intracellular protein cereblon (CRBN.) This is part of the ubiquitin ligase complex E3, which includes deoxyribonucleic acid (DNA) damage-binding protein 1(DDB1), cullin 4 (CUL4), and Roc1. E3 ubiquitin ligases are responsible for the polyubiquitination of a number of different substrate proteins and may explain the pleiotropic cellular effects observed during treatment with lenalidomide .</p><p>Lenalidomide inhibits the release of pro-inflammatory cytokines including tumour necrosis factor &alpha; (TNF- &alpha;), interleukin-1&beta; (IL-1&beta;), IL-6 and IL-12 from peripheral blood mononuclear lipopolysaccharide (LPS) stimulated cells and increases the production of the anti-inflammatory cytokine IL-10 in LPS-stimulated cells. &nbsp;</p><p>It induces the production of IL-2 and interferon-1&gamma; (IFN-1&gamma;) and increases T cells proliferation and cytotoxic activity of natural killer cells.</p><p>Lenalidomide inhibits the proliferation of various haematopoietic tumour cell lines.</p><p>&nbsp;</p><p>The combination of lenalidomide with rituximab increases the NK mediated, antibody dependent cell- mediated cytotoxicity (ADCC), the formation of immune synapses and direct apoptosis in the case of follicular lymphoma, which results in an increased anti-tumour activity of the combination compare with monotherapies.</p><p>&nbsp;</p><p>In <em>in vitro </em>angiogenesis models lenalidomide inhibits angiogenesis by preventing the formation of microvessels and endothelial cell channels as well as the migration of endothelial cells. Lenalidomide also inhibits the formation of the pro-angiogenic factor VEGF in PC-3 prostate tumour cells.</p><p>&nbsp;</p><p><em>Pharmacodynamics </em></p><p><em>Cardiac Electrophysiology QT study </em></p><p><em>&nbsp;</em></p><p><em>&nbsp;</em></p><p>No prolongation of the QTc interval was observed in healthy male subjects receiving single doses of lenalidomide at a dose of 10 mg or 50 mg.</p><p>&nbsp;</p><p><u>Clinical Efficacy</u> &nbsp;</p><p><em>Clinical experience in patients with untreated multiple myeloma who are eligible for transplant and receive lenalidomide in combination with bortezomib and dexamethasone. </em></p><p>The efficacy (according to the International Myeloma Working Group (IMWG) response criteria) and safety of lenalidomide in combination with bortezomib and dexamethasone (RVd) was evaluated in two phase-3 multicentre clinical studies: PETHEMA GEM2012 and IFM 2009.</p><p>&nbsp;</p><p><u>PETHEMA GEM2012</u></p><p>The PETHEMA GEM2012 study was a phase-3 randomised, controlled, open-label, multicentre study comparing 2 conditioning regimens (busulfan-melphalan and MEL200), administered prior to transplantation in patients who had received RVd as initial therapy. RVd was administered in six 4-week cycles (24 weeks). Patients received lenalidomide 25 mg/day orally on days 1-21, subcutaneous bortezomib 1.3 mg/m<sup>2 </sup>on days 1, 4, 8 and 11 and dexamethasone 40 mg/day orally on days 1-4 and 9- 12 of the repeated 28-day cycles. Following initial therapy, patients received either a conditioning regimen of busulfan-melphalan or MEL200 (1:1 randomisation) and ASCT. In addition, patients received two add-on treatment cycles (8 weeks) of RVd following ASCT. A total of 458 patients were enrolled in the study.</p><p>&nbsp;</p><p>At the end of the initial treatment with RVd in the PETHEMA GEM20212 study, the &ge; VGPR rate was 67%, the CR rate was 33%, and 47% (217/458) of the study subjects were MRD negative. Of the study subjects with &ge; VGPR, 64% (196/305) were MRD negative (10<sup>-4 </sup>sensitivity).</p><p>&nbsp;</p><p>The &ge; post-transplant VGPR rate was 75% and the CR rate was 44%, and 59% (287/458) of the study subjects were MRD negative. Of the study subject with &ge; VGPR, 79% (271/344) were MRD negative</p><p>(10<sup>-4 </sup>sensitivity).</p><p>&nbsp;</p><p><u>IFM 2009</u></p><p>The IFM 2009 study was a phase 3 randomised, controlled, open-label, multicentre study comparing RVd with and without ASCT as initial therapy in transplant-eligible patients with previously untreated multiple myeloma. Patients received lenalidomide 25 mg/day orally on days 1-14, intravenous bortezomib 1.3 mg/m<sup>2 </sup>on days 1, 4, 8 and 11, and dexamethasone 20 mg/day orally on days 1, 2, 4, 5, 8, 9, 11 and 12 of the repeated 21-day cycles. RVd was administered as eight 3-week cycles (24 weeks) without immediate ASCT (arm A) or as three 3-week cycles (9 weeks) prior to ASCT (arm B). Patients in arm B also received two add-on 3-week cycles of RVd after ASCT. A of total of 700 patients were enrolled in the study. &nbsp;</p><p>In the IFM 2009 study, the &ge; VGPR rate at the end of the initial therapy was 68% and the CR rate was 31%. Of the study subjects with &ge; VGPR, 57% (136/237) were MRD negative (10<sup>-4 </sup>sensitivity).</p><p>&nbsp;</p><p><em>Clinical experience with lenalidomide in patients with multiple myeloma after autologous stem cell transplantation </em></p><p><em>&nbsp;</em></p><p>The efficacy and safety of lenalidomide has been evaluated in two phase 3 multicenter, randomized, double-blind placebo-controlled, parallel-group, two-arm studies: CALGB 100104 and IFM 2005-02. The primary endpoint in both studies was progression-free survival (PFS).</p><p>&nbsp;</p><p><u>CALGB100104</u></p><p>Patients between 18 and 70 years of age with active multiple myeloma requiring treatment and no previous progression after initial therapy were included in the study.</p><p>Patients were randomized 1:1 to lenalidomide maintenance therapy or placebo within 90-100 days of ASCT. The lenalidomide maintenance dose was 10 mg once daily on days 1-28 of the repeated 28-day cycles (and was increased to 15 mg once daily after 3 months if tolerated ), and treatment was continued until disease progression.</p><p>In total 460 patients were randomised: 231 patients to lenalidomide and 229 patients to placebo. Both arms were similar in terms of demographic and disease characteristics.</p><p>&nbsp;</p><p>The study was unblinded on the recommendation of the Data Monitoring Committee after reaching a pre- defined PFS threshold in a scheduled interim analysis. After unblinding, patients in the placebo arm were allowed to cross over to the lenalidomide treatment arm prior to disease progression.</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The median follow-up time was 81.9 months at data cut-off &nbsp;&nbsp;&nbsp;&nbsp; on 01 February 2016.</p><p>The risk of disease progression or death was reduced by 39% in favour of lenalidomide (HR = 0.61; 95% CI, 0.48 to 0.76; p &lt; 0.001). The median progression-free survival was 56.9 months in the lenalidomide arm compared with 29.4 months in the placebo arm.</p><p>In the OS analysis, the observed HR was 0.61 (95% CI, 0.46 to 0.81) for lenalidomide versus placebo and indicated a 39% reduced risk of death. Median overall survival was 111.0 months in the lenalidomide arm compared with 84.2 months in the placebo arm.</p><p>&nbsp;</p><p>IFM 2005-02</p><p>Patients who were less than 65 years of age at diagnosis and underwent high-dose chemotherapy followed by ASCT and had achieved at least disease stabilization at the time of hematologic recovery were included in the study.</p><p>&nbsp;</p><p>Patients were randomized to lenalidomide maintenance therapy or the placebo arm within 6 months of ASCT. After two lenalidomide consolidation cycles (25 mg/day, on days 1-21 of a</p><p>28-day cycle), the lenalidomide maintenance dose was 10 mg once daily (1-28 of a 28-day cycle; and was increased to 15 mg once daily after 3 months if tolerated). Treatment was continued until disease progression. A total of 614 patients were randomised: 307 patients to lenalidomide and 307 patients to placebo.</p><p>&nbsp;</p><p>Treatment was discontinued in the remaining 119 study subjects receiving lenalidomide maintenance therapy (minimum treatment duration of 27 months) due to an observed uneven distribution of SPMs.</p><p>&nbsp;</p><p>The median follow-up time was 96.7 months at data cut-off on 01 February 2016. The risk of disease progression or death was reduced by 43% in favour of lenalidomide (HR = 0.57;</p><p>95% CI, 0.42 to 0.76; p &lt; 0.001). The median PFS was 44.4 months in the lenalidomide arm compared with 23.8 months in the placebo arm.</p><p>&nbsp;</p><p>For OS analysis, the observed HR was 0.90 (95% CI, 0.72 to 1.13) for lenalidomide versus placebo. Median overall survival was 105.9 months in the lenalidomide arm compared with 88.1 months in the placebo arm.</p><p>&nbsp;</p><p>Clinical experience in patients with untreated multiple myeloma who are not eligible for transplant and received lenalidomide in combination with bortezomib and dexamethasone</p><p><em>&nbsp;</em></p><p>The SWOG S0777 study evaluated the addition of bortezomib to basic treatment with lenalidomide and dexamethasone as initial therapy, followed by further treatment with Rd until disease progression in patients with treatment-naive multiple myeloma who were not due to receive stem cell transplantation in the immediate future.</p><p>&nbsp;</p><p>&nbsp;</p><p>Patients in the treatment arm with lenalidomide, bortezomib and dexamethasone (RVd) received lenalidomide 25 mg/day orally on days 1-14, intravenous bortezomib 1.3 mg/m<sup>2</sup> on days 1, 4, 8 and 11, and dexamethasone 20 mg/day orally on days 1, 2, 4, 5, 8, 9, 11 and 12 of the repeated 21-day cycles for up to eight 21-day cycles (24 weeks). Patients in the treatment arm with lenalidomide and dexamethasone (Rd) received lenalidomide 25 mg/day orally on days 1-21 and dexamethasone 40 mg/day orally on days 1, 8, 15 and 22 of the repeated 28-day cycles for up to six 21-day cycles (24 weeks). Patients in both treatment arms received the Rd regimen continuously: lenalidomide 25 mg/day orally on days 1-21 and dexamethasone 40 mg/day orally on days 1, 8, 15 and 22 of the repeated 28-day cycles. Treatment was planned to continue until disease progression.</p><p>&nbsp;</p><p>&nbsp;</p><p>The primary efficacy endpoint of the study was progression-free survival (PFS). A total of 523 patients</p><p>were enrolled in the study, of which 263 were randomised to RVd and 260 to Rd. The demographic data and disease-related baseline characteristics of the patients were well balanced between treatment arms.</p><p>&nbsp;</p><p>Results for PFS (IRAC review, EMA censoring rules), with data cut-off date of 01 December 2016 and a median follow-up period of 60.6 months in surviving subjects, showed a 24% reduction in the risk of disease progression or death in favour of RVd (HR = 0.76; 95% CI 0.62; 0.94). The median overall PFS was 41.7 months (95% CI 33.1; 51.5) in the RVd arm versus 29.7 months (95% CI 24.2; 37.8) in the Rd arm.</p><p>&nbsp;</p><p>&nbsp;</p><p>Participants in the RVd arm had a 28% reduction in the risk of death compared with the Rd arm (HR =</p><p>0.72; 95% CI = 0.56 to 0.94). Median OS was 89.1 months overall (95% CI 76.1; not evaluable) in the RVd arm compared with 67.2 months (95% CI 58.4; 90.8) in the Rd arm. Similarly, the &ge; VGPR rate was higher in the RVd arm (58%) than in the Rd arm (32%).</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Clinical experience in untreated patients who are not eligible for transplant and received lenalidomide in combination with dexamethasone </em></p><p>The safety and efficacy of lenalidomide was evaluated in a Phase-3 , multicenter, randomized, open- label, 3-arm study (MM-020) of patients who were either 65 years of age or older or who, if younger than 65 years of age, could not undergo stem cell transplantation because they refused it or because stem cell transplantation was not available to the patient for financial or other reasons. In the study (MM-020), lenalidomide plus dexamethasone (Rd) was compared with melphalan, prednisone plus thalidomide (MPT) for a maximum of twelve 42 day-cycles (72 weeks) for 2 different durations of use (i.e., until disease progression [Rd arm] or for up to eighteen 28-day cycles [72 weeks, Rd18 arm]). Patients were randomised (1:1:1) to one of the three treatment arms. Patients were stratified at randomisation by age (&le;75 years versus &gt;75 years), stage (ISS stages I and II versus stage III), and country.</p><p>&nbsp;&nbsp;</p><p>Patients in the Rd and Rd18 arms took 25 mg of lenalidomide once daily on days 1 to 21 of the 28-day cycles. Dexamethasone 40 mg was used once daily on days 1, 8, 15, and 22 of each 28-day cycle. The loading dose and regimen for Rd and Rd18 were adjusted for age and renal function. Patients over the age of 75 received a dexamethasone dose of 20 mg once daily on days 1, 8, 15, and 22 of each 28- day cycle. All patients received prophylactic anticoagulation (low molecular weight heparin, warfarin, heparin, low-dose acetylsalicylic acid) during the study.</p><p>The primary efficacy endpoint of the study was progression free survival (PFS). A total of 1,623 patients were enrolled into the study, with 535 patients randomized to Rd, 541 patients to Rd18 and</p><p>547 patients randomized to MPT. Patient demographics and disease-related characteristics were balanced between the 3 arms at baseline. In general, subjects had advanced-stage disease: 41% of the total study population had ISS stage III and 9% had severe renal impairment (creatinine clearance [CLcr] &lt; 30 mL/min). The median age was 73 in the 3 arms</p><p>PFS was significantly longer with Rd (26.0 months) than MPT (21.9 months): HR 0.69 (95% CI: 0.59-0.80 p = &lt; 0.001) indicating a 31% reduction in the risk of progression or death. In the two treatment arms, deaths during the study duration contributed to PFS at the same rate (10%) . There was a 4.3-month improvement in median PFS time in the Rd arm compared with the MPT arm . Myeloma response rate was significantly higher with Rd than with MPT (75.1% versus 62.3%; p &lt; 0.00001), with</p><p>15.1% of patients in the Rd arm achieving a complete response compared with 9.3% of patients in the MPT arm. The median time to initial response was 1.8 months in the Rd arm and 2.8 months in the MPT arm.</p><p>For the analysis of overall survival (OS), the median observation time for all surviving patients is</p><p>37.0 months, with 574 death events occurring at 64% (574/896) of the last OS events. The observed HR was 0.78 in favour of Rd versus MPT (95% CI = 0.64, 0.96; nominal p-value = 0.01685) with a 22% reduction in the risk of death.</p><p><em>Clinical experience in untreated patients who are not eligible for transplant and received lenalidomide in combination with melphalan and prednisone </em></p><p>The safety and efficacy of lenalidomide was evaluated in a Phase-3 multicenter, randomized double blind 3-arm study (MM-015) in patients who were at least 65 years of age and whose serum creatinine was &lt; 2.5 mg/dL. In the study, lenalidomide in combination with melphalan and prednisone (MPR) with or without lenalidomide maintenance monotherapy until disease progression was compared with the combination of of melphalan plus prednisone for a maximum of 9 cycles. Patients were randomized 1:1:1 to one of three treatment arms: Arm MPR+R arm &ndash; induction therapy with oral MPR combination followed by lenalidomide maintenance therapy; MPR+ p arm &ndash; induction therapy with oral MPR combination followed by maintenance therapy with placebo; MPp+ p arm &ndash; oral MPp (MP + placebo) - induction therapy with oral MPp (MP + placebo) combination followed by maintenance therapy with placebo (MPp+p).</p><p>Progression-free survival was significantly longer for MPR+R than for MPp+p, according to the blinded independent review, with an of HR 0.388 (95% CI: 0.274-0.550) indicating a 61% reduction in the risk of disease progression for MPR+R compared with MPp+p.</p><p><em>Clinical experience in patients with multiple myeloma who received at least one prior therapy </em></p><p>In two multicentre, randomised, placebo-controlled, parallel group controlled, double-blind studies with the same design (MM-009 in the US and Canada and MM-010 in Europe, Israel and Australia) 353 and 351 patients, with multiple myeloma who were previously treated with one or more chemotherapy regimens were treated with either lenalidomide plus dexamethasone or with dexamethasone.</p><p>In a pooled evaluation of both studies, the median time to progression in patients treated with lenalidomide/dexamethasone was 48 weeks (95% CI: 41.1;</p><p>60.1) and in patients on placebo/dexamethasone, it was 20.1 weeks (95% CI: 19.9, 20.7). The median duration of progression-free survival was 47.3 weeks (95% CI: 36.9, 58.4) <em>versus </em>20.1 weeks (95% CI: 18.1, 20.3). Overall survival was significantly higher with lenalidomide/dexamethasone at 90.3 vs 80.2 weeks, p=0.015, (patients in the placebo arm could switch to the active drug after progression or unblinding, 50% were treated with lenalidomide/dexamethasone).</p><p>The median duration of treatment was 28.1 weeks (min: 0.1, max: 110.7). <em>Clinical experience in myelodysplastic syndrome </em></p><p>In a phase-2 multicentre, single-arm, open label study (MDS-003 in Germany and the US), 120 patients with confirmed RBC transfusion dependence due to low- or intermediate-risk MDS or intermediate risk 1 with a 5q deletion cytogenic abnormality with or without further cytogenetic abnormalities were treated with lenalidomide 10 mg. The median duration of therapy was 52.5 weeks. The rate of transfusion- independence (&gt; 56 days) was 62.8%. The median increase in haemoglobin was 5.9 g/dl. The median duration of response was 97 weeks. Significant cytogenetic response was observed in 34.6% of patients and a less pronounced cytogenetic response in 38.5% of patients.</p><p>In a phase-3 multicentre, double-blind, placebo-controlled, three-arm study (MDS-004 in Europe and Israel), 138 patients with confirmed RBC transfusion dependence due to low or intermediate-risk MDS or intermediate risk 1 with a 5q deletion cytogenetic abnormality with or without further cytogenetic abnormalities were randomised and treated with lenalidomide 10 mg, lenalidomide 5 mg or placebo. The duration of the double-blind phase was 16-52 weeks. The rate of transfusion-independence (&gt; 182 days) was 56.1% in the 10 mg group. The corresponding transfusion-independence rates in the 5-mg and placebo groups were 41.3% and 5.9%, respectively. The median duration of response was 106 weeks in the 10-mg group; however, it could not be determined in the 5 mg and placebo groups. A clear or less clearly pronounced cytogenetic response was observed in 24.0% and 17.1% (10 mg); 10.9% and 6.5% (5 mg); and 0% and 0% (placebo) of patients.</p><p>The rate of transfusion-independence (&gt; 56 days) was 61.0% in the 10 mg group, with a median increase in haemoglobin of 6.3 g/dl. The corresponding transfusion-independence rates and haemoglobin increases in the 5 mg and placebo groups were 50.0% and 7.8%, and 5.1 g/dl and 2.3 g/dl, respectively.</p><p><em>Clinical experience in mantle cell lymphoma </em></p><p>The phase-2 multicentre, uncontrolled MCL-001 study of lenalidomide monotherapy was designed to evaluate the safety and efficacy of lenalidomide in patients with mantle cell lymphoma who had relapsed after treatment with bortezomib or a bortezomib-containing regimen or who were refractory to this treatment. Only patients with confirmed translocation or cyclin-overexpression, as well as patients who are not eligible for stem cell transplantation were included in the study. Lenalidomide was administered on days 1-21 of the repeated 28-day treatment cycles until progression, or the occurrence of unacceptable toxicity, or withdrawal of consent.</p><p>Previous treatment of the patient with an anthracycline or mitoxantrone, cyclophosphamide, rituximab, and bortezomib alone or in combination was a prerequisite for study participation.</p><p>Patients with an absolute neutrophil count (ANC) &ge; 1500 cells/mm<sup>3</sup>, platelet counts &ge;</p><p>60,000/cells/mm<sup>3</sup>, serum SGOT/AST or SGPT/ALT &lt; 3.0 x ULN ( upper limit of normal) except for documented evidence of hepatic involvement by lymphoma, serum total bilirubin &lt; 1.5 x ULN except for Gilbert&rsquo;s syndrome or documented hepatic involvement by lymphoma, and calculated creatinine clearance &gt;30 ml/min (according to the Cockcroft-Gault formula) were enrolled.</p><p>The primary efficacy endpoints of the MCL-001 study were overall response rate (ORR) and duration of response (DOR). An overview of the efficacy results for the ITT (Intent to Treat) population according to the findings by the Independent Review Committee (IRC) is provided in the table below. The median time to response was 2.2 months (1.7; 13.1 month). Median overall survival was 19.0 months (95% Cl 12.5; 22.9 months). Progression-free survival in the overall study population was 3.95 months.</p><p>&nbsp;</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:594px"><tbody><tr><td><p><strong>Evaluation of response rate </strong><strong>(n = 134) </strong></p></td><td style="vertical-align:top"><p><strong>n (%) </strong></p></td><td style="vertical-align:top"><p><strong>95% Cl </strong></p></td></tr><tr><td style="vertical-align:top"><p>Overall Response Rate (IWRC) (CR+CRu+PR)</p><p>Complete remission (CR+CRu)</p><p>CR</p><p>CRu</p><p>&nbsp;</p><p>Partial remission (PR)</p><p>Stable Disease (SD)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>37 (28)</p><p>10 (7)</p><p>2 (1)</p><p>8 (6)</p><p>27 (20)</p><p>39 (29)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>(20.2; 36.0)</p><p>(3.6; 13.3)</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:576px"><tbody><tr><td style="vertical-align:top"><p><strong>Duration of remissions (months) </strong></p></td><td style="vertical-align:top"><p><strong>Median </strong></p></td><td style="vertical-align:top"><p><strong>95% CI </strong></p></td></tr><tr><td style="vertical-align:top"><p>Duration of Overall Response (CR + CRu + PR)</p><p>N = 37</p></td><td style="vertical-align:top"><p>16.6</p></td><td style="vertical-align:top"><p>(7.7; 26.7)</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>In the MCL-002 study, a discernible increase in deaths was observed within 20 weeks in the lenalidomide arm: 13% (22/170) compared with 7% (6/84) in the control arm, in the ITT population overall. In patients with a high tumour burden, the corresponding figures were 20% (16/81) and 7% (2/28).</p><p>&nbsp;</p><p>Clinical experience in follicular lymphoma</p><p><em>&nbsp;</em></p><p>NHL-007</p><p>The study CC-5013-NHL-007 (AUGMENT) is a phase-3, multicentre, double-blind, randomised study. The efficacy and safety of lenalidomide in combination with rituximab (R<sup>2</sup>) versus rituximab plus placebo was studied in patients with relapsed/refractory indolent lymphoma.</p><p>&nbsp;</p><p>&nbsp;</p><p>A total of 358 patients aged at least 18 with FL Grades 1, 2 or 3A (n = 295) or histologically confirmed marginal zone lymphoma (MZL) were randomised at a ratio of 1:1. The patients had been previously treated with at least one systemic chemotherapy, immunotherapy or immunochemotherapy. The patients were to have received at least 2 previous doses of rituximab and were not to be rituximab refractory.</p><p>&nbsp;</p><p>Lenalidomide was administered at an oral dose of 20 mg once daily on the first 21 days of the repeated 28-day treatment cycles, over 12 cycles or until the occurrence of a non-acceptable toxicity. The rituximab dose was 375 mg/m<sup>2</sup> once weekly in cycle 1 (days 1, 8, 15 and 22) and on day 1 of every 28- day cycle from cycle 2 up to and including cycle 5.</p><p>&nbsp;</p><p>&nbsp;</p><p>The primary efficacy endpoint of the study was progression-free survival (PFS). In patients with FL, the median progression-free survial (PFS) in the R<sup>2</sup> arm was significantly longer (39.4 months; 95% CI 25.1; [NE](Not estimable)) than in the control arm (13.8 months; 95% CI: 11.2; 16.0); the risk of relapse was reduced by 60% (HR 0.40; 95% CI: 0.29; 0.55). The result of the primary endpoint was clinically and statistically significant.</p><p>&nbsp;</p><p>In addition, the FL patients showed a higher overall response rate (ORR) in the R<sup>2</sup> arm (ORR 80.3 %; 95% CI: 72.9; 86.4) compared with the rituximab monotherapy (ORR 55.4; 95% CI: 47.0; 63.6). The median response rate was 36.6 months in the R<sup>2</sup> arm and 15.5 months in the control arm. Mortality, measured as the overall survival rate (OS) after 2 years, was reduced in the R<sup>2</sup> arm by 55% (HR 0.45; 95% CI: 0.22; 0.92), in other words, after 2 years, 94.8% of the patients in the R<sup>2</sup> arm were alive compared with 85.8% of the patients receiving rituximab monotherapy.</p><p>&nbsp;</p><p>&nbsp;</p><p>NHL-008</p><p>&nbsp;</p><p>The NHL-008 study is a phase-3 open-label, randomised study in patients (n = 232) with relapsed or refractory FL (Grade 1-3B), MZL or MCL. In contrast to the NHL-007 study, the NHL-008 study included patients who were refractory to rituximab, i.e., either did not respond to the treatment or had a relapse within 6 months after treatment with rituximab, or who were refractory to rituximab as well as to chemotherapy.</p><p>&nbsp;</p><p>&nbsp;</p><p>After an initial combined treatment phase with rituximab + lenalidomide (R<sup>2</sup>) over 12 cycles, the patients were randomised to the subsequent maintenance therapy, to receive either the combination therapy R<sup>2</sup> (or optionally, lenalidomide monotherapy after cycle 18) or rituximab monotherapy.</p><p>During the induction treatment, lenalidomide was administered at a dose of 20 mg on days 1-21 of the repeated 28-day cycles, either for up to 12 cycles or until an unacceptable toxicity occurred or until consent to participate in the study was withdrawn. The rituximab dose was 375 mg/m<sup>2</sup> per week in cycle 1 (days 1, 8, 15 and 22) and on day 1 of every other 28-day cycle (cycles 3, 5, 7, 9 and 11) for up to</p><p>12 treatment cycles</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>The primary efficacy endpoint of the induction phase of the study was the overall response rate (ORR) according to the modified response criteria of the International Working Group (IWGRC) of 1999. The available results are based on the interim analysis from the initial R<sup>2</sup> treatment phase.</p><p>&nbsp;</p><p>&nbsp;</p><p>After the induction phase of 12 cycles, the ORR of all study participants with FL (n = 148) was 70.3%; rituximab refractory patients (n = 60) had an ORR of 58.3%, whilst rituximab non-refractory patients (n</p><p>= 88) had an ORR of 79.3%.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>Lenalidomide is rapidly absorbed with a T<sub>max </sub>of 1 hour. The oral bioavailability is approximately 70%. The pharmacokinetics of lenalidomide are dose-proportional.</p><p>When administered concomitantly with a high-fat meal, the extent of absorption is reduced in healthy volunteers, resulting in an approximately 20% decrease in the area under the concentration-time curve (AUC) and a 50% decrease of the C<sub>max </sub>in plasma.</p><p>Population pharmacokinetic analyses show that the oral absorption rate of lenalidomide in MCL- patients is comparable to that observed in patients with MM or MDS. <u>Distribution</u></p><p>Lenalidomide binding to plasma proteins is low (&lt;30%). Whether lenalidomide crosses the blood-brain barrier has not been studied.</p><p>Lenalidomide passes into semen (&lt; 0.01% of the dose) after administration of a daily dose of 25 mg. Three days after discontinuation of the medicinal product, lenalidomide is no longer detectable in the semen of healthy subjects.</p><p>&nbsp;</p><p><u>Metabolism</u></p><p>The metabolism of lenalidomide is minimal and does not occur via the phase I enzymes. The main component occurring in humans <em>in vivo </em>in blood is unchanged lenalidomide. 5-hydroxyl- lenalidomide and N-acetyl-lenalidomide were identified as metabolites; each of which reaches less than 5% of the blood levels of the parent substance.</p><p><u>Elimination</u></p><p>Approximately two thirds of a dose of lenalidomide is excreted unchanged via the kidneys. The renal clearance of lenalidomide exceeds the glomerular filtration rate; therefore lenalidomide is actively secreted to at least some extent.</p><p>At therapeutic doses (up to 25 mg/day), the plasma half-life is approximately 3 hours in healthy volunteers and ranges from 3 to 5 hours in patients.</p><p>Steady state concentrations are attained on day 4. There is no accumulation with multiple doses.</p><p>&nbsp;</p><p><u>Kineticsinspecialpatientgroups</u></p><p>There is no data on pharmacokinetics in paediatric patients.</p><p>Lenalidomide is primarily el i minat ed as an unchanged active substance via glomerular filtration and active tubular secretion. After a single dose of 25 mg, the AUC is increased by 25% in mild renal insufficiency (Clcr 80-50 ml/min); three-fold in moderate renal insufficiency (Clcr 50-30 ml/min) and four to five-fold in severe renal insufficiency (ClCr &lt;30 ml/min) and/or dialysis-dependent renal insufficiency (interdialytic period) . The elimination half-life is prolonged three-fold to 9-10 hours in moderate renal insufficiency.</p><p>&nbsp;</p><p>Hepatic impairments</p><p><em>&nbsp;</em></p><p>Population pharmacokinetic analysis included patients with mild hepatic impairment (n=16; total bilirubin &gt;1.0 to &le; 1.5 x ULN or AST &gt; ULN) and show that mild hepatic impairment does not affect lenalidomide disposition. No data is available on patients with moderate to severe hepatic impairment .</p><p>&nbsp;&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Short-term/long-term toxicity</p><p><em>&nbsp;</em></p><p>Lenalidomide has a low potential for acute toxicity; in rodents the lowest lethal doses after oral administration were more than 2000 mg/kg. Long-term administration of lenalidomide led to the mineralisation of the renal pelvis in rats, most notably in female animals. The dose at which no side effects occurr (<em>no observed adverse effect level, </em>NOAEL), is estimated to be less than 75 mg/kg in rats and is therefore approximately 25 times higher than the daily human exposure at a dose of</p><p>25 mg/day based on the AUC. In monkeys, repeated oral administration resulted in a dose-dependent decrease in the neutrophil count; this effect is due to the pharmacodynamic effect of the active substance. Repeated oral administration of 4 and 6 mg/kg to monkeys for a period of up to 20 weeks resulted in mortality and significant toxicity (marked weight loss, decrease in red and white blood cell count and in platelet counts, multiple organ bleeding , inflammation of the gastrointestinal tract, atrophy of the lymphoid tissue and bone marrow). Administration of 1 and 2 mg/kg/day for 52 weeks resulted in changes in the propotions of cells in the bone marrow in monkeys, a slight decrease in the ratio of myeloid to erythroid cells, and thymic atrophy. Minor suppression of the number of WBCs was observed at 1 mg/kg/day. The NOAEL was 1 mg/kg/day. AUC exposure at this dose is equivalent to human therapeutic exposure at 25 mg/day.</p><p>&nbsp;</p><p>Mutagenicity/carcinogenicity</p><p><em>in vitro </em>(bacterial mutations, human lymphocytes, mouse lymphoma, Syrian hamster embryonal cell transformation) and <em>in vivo </em>(rat micronucleus test) mutagenicity studies revealed no active substance- related effects at either the genetic or chromosomal level. Carcinogenicity studies with lenalidomide have not been performed.</p><p>&nbsp;</p><p>Reproductive toxicity</p><p><em>&nbsp;</em></p><p>Developmental toxicity studies (embryo-fetal toxicity/teratogenicity) were conducted in rats, rabbits and monkeys. In a study on monkeys, lenalidomide was given in doses up to 4 mg/kg/day. The study results show that the administration of lenalidomide to pregnant female monkeys resulted in malformations in the offspring that were comparable to thalidomide malformations.</p><p>In rabbits receiving oral administration of 3, 10 and 20 mg/kg/day, developmental toxicity at dos es of 10 and</p><p>20 mg/kg/day was characterized by slightly reduced foetal body weight, more frequent post-implantation loss (early and late resorption and intrauterine deaths) as well as macroscopic external findings in the foetuses, associated with morbidity and pharmacotoxic effects due to lenalidomide (purple discoloration of the skin over the whole body). At 10 mg and 20 mg/kg/day, soft tissue and skeletal changes were observed in the foetuses, which are however typical for rabbit strain used. The maternal and development--related NOAELs for lenalidomide in rabbits were 3 mg/kg/day.</p><p>As observed in previous rat thalidomide studies, an embryo-foetal development study in rats with lenalidomide administrations up to 500 mg/kg/day also showed no teratogenic effect. At doses of 100, 300 or 500 mg/kg/day, there was minimal maternal toxicity, including a small, temporary reduction in mean body weight gain and food intake.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Capsule contents</p><p>Anhydrous lactose</p><p>Microcrystalline cellulose</p><p>Croscarmellose sodium</p><p>Magnesium stearate</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30C. Store in the original package and out of the reach and sight of children.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lenalidomide capsules are provided in Polyvinylchloride (PVC) / Polychlorotrifluoroethylene (PCTFE) blisters with push-through aluminium foil.</p><p>Revlimid 5 mg/ 10 mg/ 15 mg/ 25 mg hard capsules Pack size of 21 capsules.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Capsules should not be opened or crushed. If powder from lenalidomide makes contact with the skin, the skin should be washed immediately and thoroughly with soap and water. If lenalidomide makes contact with the mucous membranes, they should be thoroughly flushed with water.</p><p>Any unused product or waste material should be returned to the pharmacist for safe disposal in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Celgene International Sàrl,  
Route de Perreux 1, 
2017 Boudry,  
Switzerland 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                January 2020 
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>